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Abstract
Pediatric autoimmune neuropsychiatric disorder associated with streptococcal infection
(PANDAS) starts as the child’s body has an inappropriate reaction to the immune
response for streptococcal infection. PANDAS is characterized by the sudden onset of
neuropsychiatric disorders, including obsessive-compulsive disorder (OCD), anxiety,
chorea movements, and tics. Previous research has drawn conflicting conclusions on
PANDAS treatment efficacy and long-term treatment outcomes leaving remission rates
unclear. The purpose of this qualitative phenomenological case study was to explore
parents’ perceptions of factors related to PANDAS remission. Parents of children
diagnosed with PANDAS were recruited through Facebook PANDAS support groups and
the National Institute of Mental Health Outreach Partnership Program Aspire
PANS/PANDAS newsletter and followed a link to a Qualtrics survey containing 16
questions related to perception of remission. Inclusion criteria included diagnosis of
PANDAS from a medical doctor and being the legal parent or guardian of the PANDAS
patient. No significant relationship was found between presence of remission and age or
symptom severity. The average length of time of illness before receiving PANDAS
diagnosis and treatment was 23.75 months, but length of illness before treatment was not
related to presence of remission. The greatest healing effect for PANDAS symptoms was
antibiotics; however, 85% of children in remission still had symptoms. This study sets a
foundation for future studies to explore why and how various treatments are more or less
effective, serves as a starting point for future experimental studies on treatment methods,
and serves as a roadmap for families with a PANDAS diagnosis.
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CHAPTER 1: INTRODUCTION TO THE STUDY
Pediatric autoimmune neuropsychiatric disorder associated with streptococcal
infection (PANDAS) was first described by Dr. Susan Swedo in 1998. PANDAS starts as
the child’s body has an inappropriate reaction to the immune response for streptococcal
infection. PANDAS is characterized by the sudden onset of neuropsychiatric disorders,
including obsessive-compulsive disorder (OCD), anxiety, chorea movements, and tics.
There is now an accepted diagnostic and treatment framework for PANDAS, but longterm treatment outcomes and remission rates are still unclear. Previous research has
drawn conflicting conclusions on PANDAS treatment efficacy. This study is a survey of
parents’ perceptions of PANDAS remission. The purpose of this qualitative
phenomenological study was to explore parents’ perceptions of factors related to
PANDAS remission.
Background
PANDAS Overview
In 1998, Dr. Susan Swedo discovered a link similar to that of Rheumatic Fever
and Sydenham Chorea, now known as Pediatric Autoimmune Neuropsychiatric Disorders
Associated with Streptococcal Infections (PANDAS). PANDAS is a subset of Pediatric
Acute-Onset Neuropsychiatric Syndrome (PANS). The distinction between PANS and
PANDAS is the relationship with the disorder to Group A streptococcus infection. In
PANDAS, there is a relationship between symptom onset and streptococcal infection.
PANDAS is encephalopathy caused by an autoimmune disorder (Cooperstock et al.,
2017).
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PANDAS starts as the child’s body has an inappropriate reaction to the immune
response for streptococcal infection (Blackburn & Wang, 2020; Frick & Pittenger, 2016;
Leonard & Swedo, 2001; Mink, 2016; Nave et al., 2018; Stagi et al., 2018; Williams et
al., 2019; Williams et al., 2016;). PANDAS Network estimates that this disorder affects
1 in 200 children; however, it is believed many more children are affected but have been
misdiagnosed (Dean et al., 2017; Leon et al., 2018).
PANDAS is characterized by the sudden onset of neuropsychiatric disorders,
including obsessive-compulsive disorder (OCD), anxiety, and tics (Frick & Pittenger,
2016; Leon et al., 2018; Mink, 2016; Sigra et al., 2018; Stagi et al., 2018). Basal ganglia
inflammation is a result of the body’s misguided immune response to infectious triggers;
in the case of PANDAS, it is a misguided response to the Group A streptococcal
infection. The effects of basal ganglia inflammation can include many neuropsychiatric
symptoms that resemble other illnesses, making many children go misdiagnosed. There
are many disorders and/or syndromes that resemble PANDAS. Further studies are needed
to determine the association and the biological pathways that connect streptococcal
infection, autoimmune response, and the later development of behavioral disorders (NIH,
2021; Williams et al., 2016).
PANDAS Symptoms
PANDAS is characterized by the sudden onset of neuropsychiatric disorders,
including obsessive-compulsive disorder (OCD), anxiety, and tics (Frick & Pittenger,
2016; Leon et al., 2018; Mink, 2016; Sigra et al., 2018; Stagi et al., 2018). Practitioners
have developed a diagnostic framework tool that explains whether symptoms are
categorized as mild, moderate, or severe (PPN, 2021). Basal ganglia inflammation is a
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result of the body’s misguided immune response to infectious triggers; in the case of
PANDAS, it is a misguided response to the Group A streptococcal infection. The effects
of basal ganglia inflammation can include many neuropsychiatric symptoms. See Table
1.
Table 1
Effects of Basal Ganglia Inflammation
Basal Ganglia is a relay station

Inflammation may cause:

through which neurons that control:
Mood and Emotion

OCD, Mood Lability, Anxiety, Separation
Anxiety

Behavior

OCD, Rage, Developmental Regression

Procedural Learning

Dysgraphia, Clumsiness, Decline in motor
skills

Motor Movements

Tics, Choreiform Movements, Hypotonia

Cognition

Slow Processing Speed, Memory Issues,
Decline in Cognitive Abilities, Decline in
Mathematics Ability, Sensory Learning
Deficits

Sensory

Sensitivity to light, sounds, smells, tastes,
textures, clothing

The current working hypothesis regarding the pathophysiology of PANDAS is
that a Group A Streptococcal infection takes place in a susceptible host, that then creates
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the production of antibodies to the Group A Streptococcal infection. The GAS antibodies
then cross-react with the cellular components of the basal ganglia (Blackburn & Wang,
2020; Dean et al., 2017; Frick & Pittenger, 2016; Nave et al., 2018; Snider & Swedo,
2004). In particular, these antibodies cross create in the caudate, nucleus, and putamen
(Blackburn & Wang, 2020; Dean et al., 2017; Frick & Pittenger, 2016; Snider & Swedo,
2004). The OCD, tics, and accompanying neuropsychiatric symptoms in children with
PANDAS arise as a result of the interaction of these antibodies and the neurons of the
basal ganglia (Blackburn & Wang, 2020; Dean et al., 2017; Frick & Pittenger, 2016;
Snider & Swedo, 2004).
Results from Geidd et al. (2000) show that there are participants with OCD and
tics who show enlarged basal ganglia in MRI assessment. Recent discoveries with the THelper 17 (Th17) lymphocytes show these cells drive neuronal deficits in mice in
postinfectious autoimmune encephalitis (Platt et al., 2020; Lotan et al., 2014). Basal
ganglia encephalitis, which represents the subset of PANDAS, is triggered by the Th17
cells causing blood brain barrier breakdown, therefore letting in autoantibodies, leading
to the neuropsychiatric symptoms associated with PANDAS (Dean et al., 2017; Platt et
al., 2020).
In recent research, studies are attempting to identify genetic markers and etiology
that could help diagnose PANDAS. Scientists have discovered the T-helper 17 (Th17)
cell, which is a T-cell subset that produces interleukin-17 (IL-17) (Harabuchi &
Takahara., 2019; Pilli et al., 2017; Platt et al., 2020; Tesmer et al., 2008). IL-17 is an
extremely inflammatory cytokine (Tesmer et al., 2008). Research is finding in both
human and mice studies that Th17 cells play an important role in the etiology of a group
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of immune-mediated diseases that include psoriasis, rheumatoid arthritis, multiple
sclerosis, inflammatory bowel disease, and asthma (Lotan et al., 2014; Tesmer et al.,
2008). Research findings from Platt et al. (2020) demonstrate that the Th17 cells play a
critical role in the entry of autoantibodies into the central nervous system and the Th17
cells create the pathogenesis to impair the central nervous system functions in
encephalitis syndromes (Frick & Pittenger, 2016; Lotan et al., 2014; Williams et al.,
2016).
PANDAS Treatments
Common PANDAS treatments recommended by the PANDAS Physicians
Network (PPN) protocol include adenotonsillectomy, antibiotics, corticosteroids,
plasmapheresis, cognitive behavioral therapy, and intravenous immunoglobulin (IVIG)
(Alexander et al., 2011; Ayaydin & Abali, 2010; Barzman et al., 2018; Brown et al.,
2017; Calaprice et al., 2018; Demesh et al., 2015; Kovacevic et al., 2015).
In the study by Prasad et al. (2021), researchers investigated which treatments
would be most effective and satisfactory for treating PANDAS. In the study by Prasad et
al., (2021), subjects were most commonly treated with antibiotics (n=60). Tonsillectomy
was the second most occurring treatment (n=50), then IVIG (n=24), then prescription
Rituximab (n=9), steroids (n=12), and plasma exchange (n=6). In a longitudinal study of
PANDAS treatment outcomes by Leon et al., (2018), a double-blind, placebo-control
study of 35 children who received IVIG were followed for a mean of 3.3 years and
received a variety of treatments such as antibiotics, IVIG, psychiatric medications,
cognitive behavioral therapy, or a combination.
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Because PANDAS was first discovered in 1998, long-term treatment outcomes
for PANDAS patients remains unknown or inconclusive due to lack of double-blind
placebo-controlled studies (Alexander et al., 2011; Ayaydin & Abali, 2010; Barzman et
al., 2018; Brown et al., 2017; Calaprice et al., 2018; Dean et al., 2017; Kovacevic et al.,
2015; Leon et al., 2018; Mink et al., 2016; Nave et al., 2018; Stagi et al., 2018; Williams
et al., 2016; Williams et al., 2019). Many PANDAS patients undergo a variety of
treatment methods (Hesselmark & Bejerot, 2019); therefore, conducting a study on
parents’ perspectives on treatments along with exploring factors in remission, such as
how age and length of illness relate to remission rate, was the focus of this study in order
to serve practitioners and families through future research investigating how to best treat
PANDAS.
Problem Statement
Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcal
Infection (PANDAS) is an autoimmune disorder that is a result of the body’s misguided
immune response to streptococcal infection (Frick & Pittenger, 2016; Leon et al., 2018;
Mink, 2016; Sigra et al., 2018; Stagi et al., 2018). PANDAS is characterized by the
sudden onset of neuropsychiatric disorders, including obsessive-compulsive disorder
(OCD), anxiety, tics, and chorea movements (Frick & Pittenger, 2016; Leon et al., 2018;
Mink, 2016; Sigra et al., 2018; Stagi et al., 2018). PANDAS was first discovered by Dr.
Susan Swedo in 1998, therefore long-term treatment efficacy remains unclear. Many
PANDAS patients undergo a variety of treatment methods in order to reach remission
(Calaprice et al., 2018; Hesselmark & Bejerot, 2019). Previous research has drawn
conflicting conclusions on PANDAS treatment efficacy (Ayaydin & Abali, 2010;
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Barzman et al., 2018; Brown et al., 2017; Calaprice et al., 2018; Cooperstock et al., 2017;
Demesh et al., 2015; Dop et al., 2021; Fusco et al., 2010; Kovacevic et al., 2015; Leon et
al., 2018; Lepri et al., 2019; Mink, 2016; Nave et al., 2018; Prasad et al., 2021; Rajgor et
al., 2018; Sigra et al., 2018; Spartz et al., 2017; Williams et al., 2016). This study
investigated parents’ perceptions on factors of remission in PANDAS. This study used a
qualitative design to gain understanding of the PANDAS remission experience, which
will lead to areas for future research to expand on areas of significance in factors of
remission in PANDAS.
A study by Calaprice et al. (2018) retrospectively examined long-term outcomes
of PANS/PANDAS. However, this study did not separate PANS/PANDAS and
investigated caregiver reported treatment efficacy, but did not address symptom
exacerbations or maintenance over time. Cooperstock et al. (2017) explains that symptom
exacerbations are common, but does not further explain how frequent or long-lasting
these exacerbations are. A study by Colvin et al. (2021) states that the cognitive,
graphomotor, and psychosocial challenges in PANDAS patients can be ongoing even if
the patient is not currently experiencing a symptom exacerbation. Studies by Latimer et
al. (2015) and Gruijter et al. (2021) suggest that length of illness and age could be related
to remission; however, both concluded these findings need further investigating. Cross et
al. (2021) states that at 31 months post-treatment, patients reached complete remission.
However, this study does not definitively state the journey or details of remission or
remission maintenance. Studies related to treatments leading to remission, the length of
time reaching remission takes, and other factors of remission such as age and length of
illness, are scarce.
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This study investigated parents’ perceptions on factors of remission in PANDAS.
This study examined patterns related to age, severity of illness, treatment methods, and
symptom exacerbations as factors of remission in PANDAS. Studies related to long-term
outcomes of PANDAS, effective treatments, and remission management are scarce
and/or inconclusive. This study was conducted to discover patterns leading to remission
and guide future research on exploration of factors of remission in PANDAS in addition
to serving as a road map for parents of children recently diagnosed with PANDAS.
Purpose of the Study
The purpose of this qualitative phenomenological case study was to explore
parents’ perceptions of factors contributing to the remission of PANDAS. This study
aimed to discover patterns in reaching PANDAS remission related to age, severity of
illness, treatment methods, and symptom exacerbations. The study used a 16-question
original survey on Qualtrics related to parents’ perceptions of factors of remission in
PANDAS. Findings from this study can be used in future research to discover cause and
effect relationships between treatment methods, age, and symptom severity to better
guide treatment protocols in the future.
Research Questions
RQ1: According to parents’ perceptions, which treatment is most effective in
achieving remission?
RQ2: According to parents’ perceptions, how long does achieving remission take?
RQ3: According to parents’ perceptions, is length of PANDAS illness prior to
receiving diagnosis and treatment related to achieving remission?
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RQ4: According to parents’ perceptions, is severity of PANDAS symptoms
related to achieving remission?
RQ5: According to parents’ perceptions, is age of PANDAS patient at symptom
onset related to achieving remission?
RQ6: According to parents’ perceptions, is presence of puberty related to
PANDAS symptoms?
RQ7: According to parents’ perceptions, are symptom flares experienced after
achieving remission?
RQ8: According to parents’ perceptions, is gender related to presence of
remission?
RQ9: According to parents’ perceptions, what is the most effective treatment for
remission maintenance?
Assumptions and Limitations of the Study
Limitations of this study are the parents’ perceptions, whether it is mother or
father completing the survey, as mothers and fathers could have different perceptions of
the PANDAS experience. In a study by Calaprice et al. (2018), 95% of surveys were
completed by mothers, 4% by fathers, and <1% other. Another limitation could be recall
bias, as parents may not clearly remember lengths of time or symptom severity. More
possible limitations could be conservatism, regressive bias, or consistency bias, as parents
may not remember exactly how severe the PANDAS symptoms were or the effectiveness
of various treatments at a particular time. A limitation of this study is that it did not
address specific brands, doses, or length of time various treatments were used. A
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delimitation of this study is not verifying the diagnosis of PANDAS through medical
records.
A challenge of the study was the potential varying perceptions of the definition of
remission. Studies examining remission in lupus and rheumatoid arthritis discuss the
varying definitions of remission, such as defining remission as either no clinical sign of
disease or remission on treatment (Felson, 2011; Wilhelm et al., 2016). Another
challenge was the vast number of potential treatments that could lead to remission, as
many PANDAS patients use more than one treatment (Hesselmark & Bejerot, 2019).
Theoretical Foundations of the Study
The goal of this study was to better understand the factors involved in remission
for PANDAS patients according to parents’ perceptions. Rallis and Rossman (2012, p.
18) state that the goal of qualitative research is learning by transforming data into
information that can be used. Therefore, this research is best suited for a qualitative study
to allow for the understanding of the lived experience of PANDAS families in remission
rather than quantitative research testing hypotheses since no studies on PANDAS
remission could be located. According to Creswell and Poth (2018, p. 8), qualitative
research begins with an assumption and uses interpretive and theoretical frameworks to
inform the study to address research problems by addressing a group with a human
problem, in this case, PANDAS remission. In order to study the problem, the researcher
takes a qualitative approach in order to find patterns or themes. The findings of the study
include a complex description and interpretation of the problem and its contribution to
the literature (Cresswell & Poth, 2018, p. 8). Mack et al., (2005) describes qualitative
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research as seeking to explore phenomena using more flexible instruments in order to
describe and explain relationships.
Phenomenology
According to Cresswell and Poth (2018), phenomenology has an emphasis on a
single concept or idea; in this study, this concept is remission. This study aimed to
understand parents’ perceptions of factors of remission from parents of children
diagnosed with PANDAS. As a methodological approach, phenomenology allows for the
examination of the lived experience of the journey to remission in PANDAS. Hardy
(2018, p. 20) describes phenomenology as understanding experiences as people live
through situations and experiences. The researcher’s role is to attempt to discover and
understand these lived experiences and transform the data that is collected into
information that can be useful. Using a pragmatism paradigm, the aim of this study was
to understand the experiences that can lead to solving problems. This study could be the
first of many to explore remission experiences in PANDAS that can solve issues related
to treatments and reaching remission.
There are two types of phenomenology, Hermeneutic and transcendental
(Cresswell & Poth, 2018). This study used transcendental phenomenology, which is
oriented toward the description of the experience of the participants. The researcher uses
the concept of epoche in order set aside their own experiences. The researcher bracketed
herself out of the study by understanding her own relationship with PANDAS and will
allow these experiences to be set aside so that the focus is on the experience of the
participants. Transcendental phenomenology allows the researcher to analyze the data by
reducing the information to significant statements that can be generalized into patterns or
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themes. Upon finding these themes and patterns, the researcher is able to provide a
textural description of the experience. The description of their experience, known as the
structural description, describes how the phenomenon was experienced in relation to
conditions, situations, or context. In this study, the phenomenon is remission, with trying
to gain understanding on how remission is related to other conditions such as age, length
of illness, and severity of illness.
In a phenomenological approach, the researcher moves between etic and emic
perspectives (Hardy, 2018). Hardy (2018) describes etic as the outsider’s perspective, and
it is achieved by examining and interpreting data through a psychological lens in which
the researcher finds helpful to bring an understanding of the research questions. Hardy
(2018) describes emic as the insider’s perspective, which takes a pragmatic approach to
help the researcher shape the varied nature of the explanations from the study. Using
epoche to bracket the researcher’s personal experiences out of this study, the emic can
help the researcher focus on results of the study by interpreting the varied and provisional
nature of the findings. The pragmatism paradigm asserts that the best method is one that
solves problems. This concept allows the researcher to translate the lived experiences of
remission in PANDAS families into information that can be used to guide future research
on treatment methods and remission outcomes. The transcendental phenomenological
approach allows for flexibility in the study so that the researcher can modify guidelines to
fit their research objectives (Creswell & Poth, 2018). The flexibility of this method is
useful in this study as the researcher had to create an original survey for this study since
no previous research could be found. There is also not enough literature that could be
located that could be used to develop hypotheses related to reaching remission, which is
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why the researcher chose this approach in order to create a starting point of research on
PANDAS remission.
Data in this study were analyzed using a transcendental phenomenological
approach. The intent of this approach in this study is that the researcher attempts to make
sense of the phenomenon, remission, under investigation. Creswell and Poth (2018)
describe phenomenology as describing the personal experiences with the phenomenon
under study. The phenomenon seeking to be better understood in this study is the process
of remission in PANDAS. Phenomenology creates a description of what the participants
in the study experienced and how the experience happened, and it aims to capture the
essence of the phenomenon (Creswell & Poth, 2018, p. 201). By using a transcendental
phenomenological approach, the researcher is able to find themes and patterns in the
phenomena under investigation. In a transcendental phenomenological case study, reality
needs to be interpreted.
This study took a direct interpretation approach, which allowed the researcher to
look at factors of remission in PANDAS and extrapolate the data in more meaningful
ways (Cresswell & Poth, 2018, p. 206). Mack et al. (2005) notes that an advantage of
qualitative research is the flexibility in data collection. This study used Wolcott’s (1994)
approach to validation with the premise that in this study validity of a survey tool would
neither guide nor inform the qualitative research, as the goal is to gain a better
understanding of PANDAS remission (Cresswell & Poth, 2018, p. 255). Wolcott (1994)
states that understanding is better than validity, and the goal of this study is better
understanding of PANDAS remission (Cresswell & Poth, 2018, p. 255).
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Instruments used to measure remission in other diseases, such as systemic lupus
erythematosus and rheumatoid arthritis have been developed. Remission can have several
definitions depending on the patient and their experience. Some examples of various
definitions of remission include clinical remission, complete remission, clinical remission
on treatment, and complete remission on treatment (Wilhelm et al., 2016). In rheumatoid
arthritis, the remission is typically measured using a cut off score on the disease activity
score (DAS28) (Gul et al., 2021). To date, there is no validated instrument specifically
for the measurement of PANDAS remission. Therefore, lack of definition of remission is
a limitation of this study, as survey participants may describe remission differently.
Balancing these approaches allowed for logical generalizations related to PANDAS
remission to be analyzed to contribute to areas of need in future research.
Biblical Foundations of the Study
The aim of this study was to gain parents’ perceptions of PANDAS remission, so
that this study could provide hope for parents currently battling PANDAS and provide
them with information to help them persevere. The love of a parent for their child keeps
them hoping for remission and helping their child in any way they can. The Bible states
the importance of hope and love in 1 Corinthians 13:13, “Now these three remain, faith,
hope, and love, but the greatest of these is love.” A parent’s love for their child
encourages them to press on during difficult times of illness. Proverbs 24:16 says,
“Though a righteous man falls seven times, he rises again.” As the illness typically takes
time to heal and many periods without worldly support or answers, Ephesians 6:11-12
says, “Put on the whole armor of God, that you may be able to stand against the schemes
of the devil. For we do not wrestle against flesh and blood, but against the rulers, against
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the authorities, against the cosmic powers over this present darkness, against the spiritual
forces of evil in the heavenly places.” Literature on remission is scarce and inconclusive.
PANDAS parents do not know what they are up against or for how long when receiving a
PANDAS diagnosis. In regard to keeping hope and persevering on the road to remission,
the Bible tells us in John 16:33, “I have told you these things, so that in me you may have
peace. In this world you will have trouble. But take heart! I have overcome the world.”
During times of uncertainty when dealing with a PANDAS diagnosis of a child,
parents must equip themselves with the armor of God to persevere through the disorder to
reach remission. In 2 Corinthians, Paul prays to have the thorn from his flesh removed on
three different occasions, but God does not remove it and explains that it is beneficial to
him. 2 Corinthians 12:7-9 states, “To keep me from becoming conceited because of these
surpassingly great revelations, there was given me a thorn in my flesh, a messenger of
Satan, to torment me. Three times I pleaded with the Lord to take it away from me. But
he said to me, ‘My grace is sufficient for you, for my power is made perfect in
weakness.’ Therefore, I will boast all the more gladly about my weaknesses, so that
Christ's power may rest on me.” Parents must keep in mind in dealing with this illness
that His power is made perfect in our weakness, such as the weakness of a child with an
illness. Parents have to persevere for the sake of their children. As parents hope faithfully
for remission, they can take comfort in God’s promises and eventual healing.
Deuteronomy provides an example that although the family may be in a current
uncomfortable place, it is not permanent. With God all things are possible, including
remission. Parents keep hope that one day their child will no longer be battling this
illness. Deuteronomy 1:6 says, “You have been at this mountain long enough. It is time to
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move on.” Although parents are rightfully discouraged, they must remember to put their
faith in God and wait for His timing for healing. Hebrews 12:1 says, “And let us run with
perseverance the race marked out for us.”
Definition of Terms
The following is a list of definitions of terms that are used in this study.
Adenotonsillectomy– Surgical removal of the tonsils and adenoids (Demesh, 2015).
Antigen- a toxin or other foreign substance that induces an immune response in the body
to create antibodies (Rose & Mackay, 2006).
Autoimmune- A disease in which the body's immune system mistakes its own healthy
tissues as foreign and attacks them, whether directed against foreign antigens or selfantigens (Rose & Mackay, 2006). Most autoimmune diseases cause inflammation (Rose
& Mackay, 2006).
Chorea– Involuntary, ongoing, random-appearing sequences of movement (Yilmaz &
Mink, 2019).
Dysgraphia- Learning disorder where writing skills are below expected level for age
and/or cognitive level. Can include decline in handwriting abilities due to psychiatric
issue and can include decline in handwriting readability and margin drift (Chung & Patel,
2015).
Flare- Worsening of PANDAS related symptoms and/or loss of function (Gromark et al.,
2022).
IVIG– Intravenous Immunoglobulin (Kovacevic, 2015).
PANDAS– Pediatric autoimmune neuropsychiatric disorder associated with streptococcal
infection (Swedo et al., 1998).
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PANS- Pediatric autoimmune neuropsychiatric syndrome, PANDAS is a subset of
PANS. PANS does not have a direct link to streptococcal infection as does PANDAS and
can be brought on my many infections (Swedo et al., 2015).
Sequela- a long-term effect of a temporary disease or injury (Rose & Mackay, 2006).
Streptococcal Infection- Commonly known as “strep throat”
Tics– Sudden, rapid, recurrent motor movement tics, such as shrugging or neck twisting,
or vocalization, such as throat clearing or coughing (Ueda & Black, 2021).
Significance of the Study
The results of this study allow for drawing introductory conclusions about
remission, as the disorder is still new enough at the time of this study that the literature is
lacking in long-term outcomes. It is not clear what type of remission is the goal in
PANDAS, as remission could mean complete remission, clinical remission, complete
remission on treatment, or clinical remission on treatment. As a parent, it is scary to not
know what to expect regarding treatment and remission, therefore it was an aim of this
study to provide hope and a road map for parents who have a child with this disorder.
This study serves as a stepping stone for future research to be able to examine more
closely how symptom severity, age, and length of illness can be further investigated to
guide treatment plans to help children with PANDAS receive appropriate and curative
treatments.
Summary
In 1998, Dr. Susan Swedo first described PANDAS as the association between
Group A Streptococcal infection and neuropsychiatric disorders. The medical community
has been slow to accept PANDAS as a diagnosis, regardless of families who can show
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vast improvement and complete healing for the child through PANDAS treatment
protocols. PANDAS Network estimates approximately 1 in 200 children suffer from
PANDAS (Leonard & Swedo, 2001). This number is hard to estimate because it is
believed so many children go misdiagnosed due to lack of practitioner knowledge on
PANDAS. Future research should be aimed at creating practitioner and community
awareness of PANDAS, exploring which treatment methods are most effective in
reaching remission of PANDAS, and research on why some treatments are more effective
than others and how to maintain remission.
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CHAPTER 2: LITERATURE REVIEW
Introduction
PANDAS starts as the child’s body has an inappropriate reaction to the immune
response for streptococcal infection. Research by Snider and Swedo (2004) found a
postinfectious autoimmune-mediated etiology for children with sudden onset of
Obsessive-Compulsive Disorder (OCD) and tics. This reaction creates brain changes in
the child, which leads to symptoms such as OCD, anxiety, tics, personality changes,
decline in math and handwriting abilities, sensory sensitivities, restrictive eating, and
more (Dean, et al., 2017; Frick & Pittenger, 2016; Leon et al., 2018; Mink, 2016; Sigra et
al., 2018; Stagi et al., 2018). PANDAS Network estimates that this disorder affects 1 in
200 children, however many children are misdiagnosed. Most PANDAS research is
based on the hypothesis that certain infections can trigger changes in both behavior and
movement in children (Murphy et al., 2007). Many doctors who are not educated on
PANDAS will diagnose the child with OCD, anxiety, Tourette Syndrome (TS), autism, or
Attention-Deficit-Hyperactivity-Disorder (ADHD), rather than finding the issue creating
the symptoms. This is an issue because the symptoms the child is presenting with are due
to the inflammation of the brain and a result of an autoimmune response, and with proper
treatment, the child will no longer have these neuropsychiatric disorders. In PANDAS,
the autoimmune response triggers basal ganglia inflammation of the brain, which leads to
the neuropsychiatric symptoms. In the 1980s, studies of children with Sydenham Chorea
found that it could serve as a useful model of pathophysiology for childhood onset
neuropsychiatric symptoms, which led to the development of PANDAS (Leonard &
Swedo, 2001).
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Basal ganglia inflammation is a result of the body’s misguided immune response
to infectious triggers; in the case of PANDAS, it is a misguided response to the Group A
streptococcal infection. The effects of basal ganglia inflammation can include many
neuropsychiatric symptoms.
Description of Research Strategy
Identification and Selection of Studies
The literature search was performed using the Jerry Falwell Library online
database. Inclusion criteria were peer-reviewed journal articles in English of any date
range, with 81% being published between 2015 and 2021. Searches were conducted in
Spring 2021 and again in Fall of 2021, and primarily used key search terms PANDAS,
Pediatric Autoimmune, Streptococcal, Sydenham Chorea, autoimmune tonsillectomy, and
autoimmune intravenous immunoglobulin.
Identification and Selection of Biblical Study
Biblical word study was performed using Bible Gateway, Study Light, and
Nave’s Topical Bible Concordance Online. Word study searches were conducted using
key search terms persevere, perseverance, hope, and endurance.
Review of Literature
PANDAS Overview
PANS/PANDAS is encephalopathy caused by an autoimmune disorder
(Cooperstock et al., 2017). Encephalitis is severe inflammation of the brain that includes
many possible causes and complex diagnosis (Li et al., 2021). Cooperstock et al., (2017)
provides a consensus on management guidelines from PANS/PANDAS experts who
gathered at the PANS/PANDAS consortium. At the consortium, the experts gathered to
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create a much-needed guideline for diagnosis and treatment of children suffering from
PANS/PANDAS. Both PANS and PANDAS are associated with the body’s misguided
response to infection (Sigra et al., 2018). Mora et al. (2020) states that childhood immune
activation by both viral and bacterial infections may increase the risk of neuropsychiatric
disorders. PANS/PANDAS is characterized by the sudden onset of neuropsychiatric
disorders, including obsessive compulsive disorder (OCD), anxiety, and tics (Sigra et al.,
2018). The most common infections that can lead to PANS/PANDAS include infections
of the upper respiratory tract, which can include rhinitis, sinusitis, and pharyngitis
(Cooperstock et al., 2017). The most common infection related to PANS/PANDAS is
Group A Streptococcus (GAS). If the onset of symptoms is able to be linked to a GAS
infection, the patient is diagnosed as PANDAS; if the onset of symptoms is unable to be
linked to a GAS infection, the patient is diagnosed PANS. However, many infection
types can trigger an immune response to onset or exacerbate symptoms, therefore, it is
likely PANS/PANDAS nonspecific immune activation mechanisms contribute to the
symptoms of PANS/PANDAS (Cooperstock et al, 2017).
PANDAS Etiology
Basal ganglia inflammation is a result of the body’s misguided immune response
to infectious triggers; in the case of PANDAS, it is a misguided response to the Group A
streptococcal infection (Alexander et al., 2011; Ayaydin & Abali, 2010; Barzman et al.,
2018; Brown et al., 2017; Bruijn et al., 2020; Calaprice et al., 2018; Dean et al., 2017;
Kovacevic et al., 2015; Leon et al., 2018; Mink et al., 2016; Nave et al., 2018; Stagi et al.,
2018; Williams et al., 2019; Williams et al., 2016). The effects of basal ganglia
inflammation can include many neuropsychiatric symptoms that resemble other illnesses,
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making many children go misdiagnosed (Goncalves et al., 2018). Further studies are
needed to definitively describe the association and the biological pathways that connect
streptococcal infection, autoimmune response, and the later development of behavioral
disorders. The current working hypothesis regarding the pathophysiology is that a GAS
infection takes place in a susceptible host, that then creates the production of antibodies
to the GAS infection that then cross-react with the cellular components of the basal
ganglia. The neuropsychiatric symptoms in children with PANDAS arise as a result of
the interaction of these antibodies and the neurons of the basal ganglia (Dean, et al.,
2017; Frick & Pittenger, 2016; Kovacevic et al., 2015; Leon et al., 2018; Mink, 2016;
Sigra et al., 2018; Stagi et al., 2018).
The exact mechanism of pathogenesis of GAS related neuropsychiatric disorders
has not been exclusively proven, but it is proposed that the autoimmune mechanism by
antibodies against the GAS infection bind to different brain regions in the basal ganglia
altering neurotransmission (Li et al., 2021; Mora et al., 2020; Xu et al., 2021). A study by
Quagliariello et al. (2018) concludes that streptococcal infection can alter gut microbiota
in children with PANDAS leading to a pro-inflammatory status through the selection of
specific bacterial strains associated with gut inflammation and immune response
activation.
Sydenham Chorea
In the 1980s, studies of children with Sydenham Chorea (SC) found that it could
serve as a useful model of pathophysiology for childhood onset neuropsychiatric
symptoms, which led to the development of PANDAS (Swedo, 1998). PANDAS has
been conceptualized as a forme fruste of SC (Kovacevic et al., 2015; Swedo et al., 2015).
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SC is a neurological disorder of childhood resulting from infection from GAS infection.
SC is an autoimmune response to a variant of streptococcus, like PANDAS. SC is a
subset of rheumatic fever. SC creates irregular and involuntary movements of the body,
known as choreiform movements (Kovacevic et al., 2015; Williams & Swedo, 2015).
Choreiform movements are also a symptom of PANS/PANDAS. The random choreiform
movements with PANS/PANDAS and Sydenham Chorea are a result of the autoimmune
response to the streptococcal bacteria resulting in inflammation of the basal ganglia of the
brain.
Symptoms of SC are characterized by rapid, irregular, and involuntary
movements of the arms and legs, trunk, and facial muscles known as chorea movements
and may include: uncoordinated movements, muscular weakness, stumbling and falling,
slurred speech, difficulty concentrating and writing, and emotional instability.
The symptoms of SC can vary from a halting gait and slight grimacing to
involuntary movements that are frequent and severe enough to be incapacitating (Yilmaz
& Mink, 2020). There is no specific treatment for SC. When the severity of movements
interferes with rest, sedative drugs, such as barbiturates or benzodiazepines, may be
needed (Yilmaz & Mink, 2020).
Most children will make a full recovery from SC, although a small number will
continue to have disabling, persistent chorea despite treatment (Yilmaz & Mink, 2020).
Doctors recommend that children who have had SC take penicillin over the course of 10
years to prevent additional manifestations of rheumatic fever (Yilmaz & Mink, 2020). A
study by Fusco and Spagnoli (2018) found that corticosteroids were effective in both
short and long-term treatment of SC. A study by Favaretto et al. (2020) concluded that
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corticosteroid treatment was effective for SC. Treatment and research regarding
rheumatic fever and SC has helped guide discovery and treatment of PANDAS.
PANDAS Pathogenesis
Li et al. (2021) states that recent studies have been successful at elucidating the
causal relationship between autoimmune central nervous system diseases and infections.
Li et al. (2021) describes the process of postinfectious autoimmune encephalitis as
occurring in three stages: the infection activating the immune response, which leads to
antibody production and tissue damage, then the injured tissue releases antigens that are
taken up by antigen-presenting cells, which leads to the production of autoantibodies.
In recent research, studies are attempting to identify genetic markers and etiology
that could help diagnose PANDAS. Scientists have discovered the T-helper 17 (Th17)
cell, which is a T-cell subset that produces interleukin-17 (IL-17) (Tesmer et al., 2008).
IL-17 is an extremely inflammatory cytokine (Tesmer et al., 2008). Research is finding in
both human and mice studies that Th17 cells play an important role in the etiology of a
group of immune-mediated diseases, that includes psoriasis, rheumatoid arthritis,
multiple sclerosis, inflammatory bowel disease, and asthma (Tesmer et al., 2008).
PANDAS is brought on as a response to streptococcal infection, and one of the areas of
etiology is between the Th17 cell and Streptococcus Pneumoniae (Tesmer et al., 2008).
Research findings from Platt et al., (2020) demonstrate that the Th17 cells play a critical
role in the entry of autoantibodies into the central nervous system and the Th17 cells
create the pathogenesis to impair the central nervous system functions in encephalitis
syndromes, such as inflammation of the basal ganglia in PANDAS.
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T-Helper 17 (Th17) Lymphocytes
Discoveries with the T-Helper 17 (Th17) lymphocytes show these cells drive
neuronal deficits in mice in postinfectious autoimmune encephalitis (Platt et al., 2020; Xu
et al., 2021). Th17 cells have been implicated in the brains of several central nervous
system diseases, including multiple sclerosis, autism spectrum disorders, epilepsy, and
Alzheimer’s. Basal ganglia encephalitis, which represents the subset of PANDAS, is
triggered by the Th17 cells causing blood brain barrier breakdown, therefore letting
autoantibodies cross the blood-brain barrier, leading to the neuropsychiatric symptoms
associated with PANDAS (Li et al., 2021; Mora et al., 2020; Platt et al., 2020; Xu et al.,
2021). In mice with GAS infection, Th17 lymphocytes were activated and migrated from
the nose to the brain (Li et al., 2021). These Th17 lymphocytes cause the breakdown of
the blood brain barrier and allow the autoantibodies to enter the central nervous system
(Li et al., 2021; Mora et al., 2020). Li et al. (2021, p.31) also states that, “The Th17
lymphocytes also activate microglia and impair neuronal circuits. Thus, Th17
lymphocytes are a potential target for the treatment of autoimmune encephalitis.”
In preclinical animal models, the induction of PANDAS has been performed
through injection of the GAS antigen (Mora et al., 2020). The immune effects of the GAS
antigen or antibodies in the animal models increased the immunoglobulin IgG antibodies
and immunoglobulin-like receptors in the serum plasma levels and within areas of the
brain including the striatum, the thalamus, and the frontal cortex (Mora et al., 2020). In
animal models, the behavioral assessment of animals exposed to GAS showed long-term
changes in various aspects of behavior, including locomotion, cognition, and emotion
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(Mora et al., 2020). Results from Geidd et al. (2000) show that there are subjects with
OCD and tics that show enlarged basal ganglia in MRI assessment.
In a study by Rodriguez et al. (2019), patients with OCD had significantly higher
levels of Th17 cells than healthy controls. The study by Rodriguez et al. (2019) also
discovered that the levels of Th17 cells progressively increased with the duration and
severity of OCD. The results of this study provide further evidence of the involvement of
immune dysregulation in the pathophysiology of OCD. In a study by Gerentes et al.
(2019), results showed that inflammation involving the immune system was observed in
patients with OCD, suggesting that possible treatment of OCD could benefit from further
studies targeting infection and inflammation as OCD treatment options. Platt et al.,
(2017) states that because the blood-brain barrier permeability is the avenue of
autoimmune encephalitis, future treatment avenues could rely on modulating the bloodbrain barrier using biological or chemical therapeutics such as reactivation of the
signaling pathways that normally function to form the blood brain barrier during
development, could be used to repair the dysfunctional barrier during disease.
There is still much to learn regarding the etiology of PANDAS. Further
investigating the role of the Th17 cells contributions in the central nervous system
autoimmunity diseases could help lead to the development of improved diagnostic tools
which could lead to immunotherapeutic treatments that are targeted against T cells or
their cytokines, that could be more effective than current treatment regimens (Li et al.,
2021; Pilli et al., 2017).
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Antibodies and Molecular Mimicry
The pathogenesis of acute rheumatic fever, rhematic heart disease, Sydenham
Chorea, and other autoimmune sequelae is related to autoantibodies that are characteristic
of autoimmune disease and result from the immune response to GAS (Chain et al., 2020;
Cunningham, 2019; Kovacevic et al., 2015). PANDAS has been conceptualized as a
forme fruste of Sydenham Chorea (Kovacevic et al., 2015). Using SC as a forme fruste to
PANDAS is a way to attempt to understand the pathogenesis of PANDAS. The sharing
of host and streptococcal epitopes leads to molecular mimicry between the streptococcal
and the host antigens that are recognized by the autoantibodies during the host response
(Bruijn et al., 2020; Cunningham, 2019; Kovacevic et al., 2015). When two antigens
share an identical epitope or when two different epitopes have similar shapes or charges,
it is possible for an antibody produced for one epitope to cross-react against the other the
process of molecular mimicry (Chain et al., 2020; Cunningham, 2019; Dean et al., 2015).
Cross-reactive antigens are molecules on the group A streptococcus that mimic host
molecules and during infection or immunization induce an autoimmune response against
host tissues leading to the autoimmune group A streptococcal sequelae (Cunningham,
2019). Molecular mimicry is used to describe the immunological cross-reactivity between
the host and the bacterial antigens (Chain et al., 2020; Cunningham, 2019; Swedo et al.,
2015). A study by Xu et al. (2021) discusses PANDAS resulting from the postinfectious
production of antibodies that target the basal ganglia through the phenomenon of
molecular mimicry. This hypothesis is drawn from the pathophysiology of Sydenham
Chorea. Results from the study by Xu et al. (2021) finds that PANDAS serum IgG shows
selectively elevated binding to cholinergic interneurons in mice striatum’s.
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Immunological cross-reactions between streptococcal and host molecules have
been identified by antibodies or T cells that react with streptococcal components and
tissue antigens (Cunningham, 2019). In a study by Frick et al. (2018), antibodies in serum
from children with PANDAS bound to ~80% of cholinergic interneurons, which was
significantly higher than the only <50% of binding seen in healthy controls. Elevated
binding to cholinergic interneurons resolved with symptom improvement after treatment
with intravenous immunoglobulin (Frick et al., 2018). Antibody-mediated dysregulation
of striatal cholinergic interneurons provides further information on the pathophysiology
of PANDAS.
Genetic Considerations of PANDAS
GAS infection causes autoimmune sequelae in many target tissues, including
tissues of the heart, kidneys, and central nervous system that manifest as acute rheumatic
fever and Sydenham chorea, and PANDAS. It is hypothesized that predisposition to postGAS autoimmunity has a genetic component since rhematic fever, Sydenham chorea, and
PANDAS are all sex-skewed (Platt, 2019; Swedo et al., 2015). PANDAS is more
prevalent in boys than girls at a rate of 3:1 (Calaprice et al., 2018; Platt, 2019). Platt
(2019) states that genome wide association studies have implicated major
histocompatibility class I and class II alleles in acute rheumatic fever, Sydenham Chorea,
Autoimmune Encephalitis, and Acute Disseminated Encephalomyelitis. Platt (2019)
states that genome wide association studies have demonstrated a genetic predisposition
for recurrent childhood infections. A study by Jones et al. (2019, p.309) concluded that
maternal autoimmunity can activate fetal microglia or alter transcription of
neurodevelopment vulnerability or immune genes in utero, and it is, “an environmental
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factor that increases the expression and severity of neurodevelopmental problems and
susceptibility to deteriorations after infectious or stress stimuli.” Han et al. (2021)
concluded that maternal inflammation in pregnancy can program the fetal inflammatory
pathways and epigenetic machinery, which could potentially result in increased
expression of neurodevelopmental disorders in children. Factors of maternal immune
activation triggered by inflammation can include factors such as obesity, gestational
diabetes, pre-eclampsia, smoking, pollution, low socioeconomic status, depression,
psychosocial stress, autoimmune disease, and asthma (Han et al., 2021). In a study by
Rea et al. (2021), of the 62 PANS/PANDAS participants, 28 reported having relatives
with psychiatric disorders, 7 reported having relatives with cardiovascular disorders, and
13 with metabolic disorders.
PANDAS Symptoms
Dean et al. (2015) states that post streptococcal movement and psychiatric
disorders continues to expand from SC to now include tics, TS, OCD, and anorexia,
among others. PANDAS is a clinical diagnosis, meaning there is no lab test to
definitively diagnose PANDAS. Criterion for diagnosis of PANDAS includes the patient
experiencing at least one of the three following: an acute and dramatic onset of
obsessions and compulsions, experiencing an acute and dramatic onset of eating
restrictions, and/or experiencing an acute and abrupt onset of motor and/or vocal tics
(Kovacevic et al., 2015; McClelland et al., 2015; Snider & Swedo, 2004; Swedo et al.,
2015). Comorbid symptoms must include at least two of the following: elevated anxiety
or separation anxiety, emotion lability and/or depression, irritability, aggression, and/or
severe oppositional behaviors, behavioral regression, sudden deterioration in school
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performance (dysgraphia, decline in memory, math difficulty), motor movement changes,
tics, or sensory abnormalities, and somatic signs including sleep disturbances or urinary
frequency (McClelland, et al., 2015; Swedo et al., 2015; Kovacevic et al., 2015; Snider &
Swedo, 2004).
Tourette Syndrome and Tics
One of the criteria for clinical diagnosis of PANDAS includes sudden onset of tic
disorder. Tourette syndrome (TS) is a neurological disorder that causes sudden,
repetitive, rapid, and unwanted movements or vocal sounds called tics. Tourette
syndrome is one of a group of disorders of the developing nervous system called tic
disorders. There is no cure for Tourette syndrome, but there are treatments to help
manage symptoms. Tics caused by TS come and go across time, can be mild to severe,
and are classified as simple or complex. Tics can be motor tics, which are tics that
involve movement, or vocal tics, which involve sound. Simple tics are sudden, brief,
repetitive movements that involve a limited number of muscle groups. Simple tics are
more common than complex tics. Complex tics are distinct, coordinated patterns of
movement that involve several muscle groups (Ueda & Black, 2021). Examples of simple
motor tics can include eye blinking, facial grimacing, shoulder shrugging, and head or
shoulder jerking (NIH, 2021). Examples of complex motor tics can include facial
grimacing that includes a head twist and shoulder shrug. Complex motor tics can appear
more purposeful, and can include things like hopping, jumping, or bending. Examples of
simple vocal tics can include things like repetitive throat clearing, sniffing, barking, or
grunting sounds. Examples of complex vocal tics may include things like repeating words
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or phrases, or although more rarely, can include coprolalia, which is using vulgar,
obscene, or swear words repetitively (NIH, 2021).
Many individuals with TS have additional co-occurring neuropsychiatric
disorders, which can include ADHD, OCD, anxiety, learning disabilities, behavior or
conduct issues, problems falling or staying asleep, social deficits, and sensory processing
issues. TS is a clinical diagnosis in which doctors evaluate if there is presence of both
motor and vocal tics that occur several times a day, every day, or intermittently for at
least one year, onset of tics occurs before age 18, and the tics are not a side effect of
medication or other medical conditions (Baglioni et al., 2019; Ueda & Black, 2021).
Some people do not require treatment for TS if the tics do not interfere with their daily
lives. Treatment options help to manage the symptoms but do not treat the underlying
disease. Medications that block dopamine, alpha-adrenergic agonists, stimulant
medications, and antidepressants are some of the commonly used medications to manage
TS symptoms. However, these medications can all have serious side effects (Baglioni et
al., 2019; Ueda & Black, 2021).
Chorea Movements
One of the comorbid symptoms in the diagnostic criteria of PANDAS includes
motor tics and/or movements. Streptococcal infection has been shown to cause
neuropsychiatric issues as well as choreiform movements. Chorea movements, whether in
PANDAS or Sydenham Chorea, are arrhythmic, rapid, and often jerky movements
(Murphy, et al., 2007; Singer, 2017). These movements can affect the entire body or only
certain regions. Chorea movements can be challenging to diagnose as they can also
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present in subtle ways or ways that just appear to be fidgety rather than chorea
movements (Murphy et al., 2007; Singer, 2017).
Sydenham Chorea can show as a wide variety of symptoms following the
streptococcal Group A infection. Sydenham Chorea involves both motoric and behavioral
symptoms. Motoric symptoms are things like chorea and dysgraphia, which is decrease
handwriting ability, and behavioral symptoms such as emotionality and anxiety (Murphy
et al, 2007; Singer, 2017). PANDAS also presents as a wide variety of symptoms, such as
anxiety, chorea movements including dysgraphia, decreased cognitive ability, and OCD
(Murphy et al., 2007).
Murphy et al. (2007) sought to discover the rate of prevalence of chorea
movement disorders after recent GAS infection and concluded that GAS infection did
lead to higher rate of chorea movements. GAS has already been etiologically related to
onset of Sydenham Chorea, Rheumatic Fever, and obsessive-compulsive disorder. In
previous studies, streptococcal titers positively correlated with obsessive compulsive rate
and severity. Murphy et al. (2007) also concluded that there was a positive relationship
found between GAS infection and the incidence of Attention-Deficit Hyperactivity
Disorder (ADHD).
Obsessive Compulsive Disorder
One of the three main criterion for PANDAS diagnosis includes sudden dramatic
onset of obsessions and compulsions. Obsessive Compulsive Disorder (OCD) in children
is characterized by recurrent and persistent thoughts, impulses, obsessions, and/or
repetitive behaviors or compulsions that aim to prevent, reduce, or neutralize the anxiety
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or distress caused by the obsessions (Rodriguez et al., 2019). The thoughts are the
obsessions, and the behaviors are the compulsions. Symptoms of OCD can include:
•

Unwanted thoughts, impulses, or reappearing images that occur repeatedly which
lead to anxiety and distress

•

Thinking about silently or repeating out loud certain words or phrases

•

Repeating actions, such as frequent handwashing or placing things in certain order

•

Having to complete certain tasks over and over according to rules in order to
alleviate the obsession (Westwell-Roper & Stewart, 2019).

In children with OCD, children complete the behaviors associated with OCD because
they think the behaviors will prevent bad things from happening or relieve anxiety in
some way. However, the actual behavioral actions are typically not connected to any
actual danger of bad things that happen. The behaviors can also be extreme, such as
handwashing multiple times in one hour. Behaviors and compulsions can change over
time. There is no cure for OCD, but there are treatment options available to help with
symptoms. Treatment for OCD typically includes types of therapy, such as behavior
therapy or cognitive-behavioral therapy (Westwell-Roper & Stewart, 2019).
Rodriguez et al. (2019) states that there is growing evidence that the immune system
may play a role in the pathogenesis of OCD in patients with microglial dysfunction and
autoimmune responses involving the levels of pro-inflammatory cytokines and antineuronal antibodies. In children with OCD, Rodriguez et al. (2019) found that there was a
greater production of pro-inflammatory cytokines in children with OCD and that Positron
Emission Tomography (PET) studies of these children indicated increased microglial
activation in the neurocircuitry of OCD (Westwell-Roper & Stewart, 2019).
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Attention-Deficit/Hyperactivity Disorder
Comorbid diagnostic criteria for PANDAS includes emotional lability and/or
depression, irritability, aggression or severe oppositional behaviors, and sudden
deterioration in school performance. This could be attributed to symptoms similar to
those of Attention-Deficit/Hyperactivity Disorder (ADHD). ADHD occurs when a person
shows a persistent pattern of inattention and/or hyperactivity-impulsivity that interferes
with daily living and/or development (CDC, 2021). Practitioners use the American
Psychiatric Association’s Diagnostic and Statistical Manual, Fifth Edition (DSM-5) to
help make an ADHD diagnosis. Using the DSM-5 helps create a standard of diagnosis
and care for those suffering from ADHD. Symptoms of ADHD include inattention,
hyperactivity, and impulsivity. In addition to displaying these symptoms, the following
conditions must be met:
•

Several inattentive or hyperactive-impulsive symptoms present before age 12

•

Several symptoms present in multiple settings (home, school, work, etc.)

•

Symptoms must interfere with or reduce the quality of daily life in social, school,
or work functioning

•

Symptoms are not easier explained by another condition, such as mood, anxiety,
or personality disorders

•

Symptoms can present as a combined presentation (NIH, 2021).

There is no cure for ADHD. Stimulants are the most widely used ADHD medications.
Between 70-80% of children with ADHD have fewer ADHD symptoms when taking
stimulants (CDC, 2021). Nonstimulants were approved for the treatment of ADHD; they
do not work as quickly as stimulants, but their effect can last up to 24 hours (CDC, 2021).
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Behavior therapy is another treatment option for ADHD and is used to modify behaviors
in varying situations to reduce symptom exacerbation (CDC, 2021).
Autism Spectrum Disorder
Comorbid diagnostic criteria for PANDAS include emotional lability and/or
depression, irritability, aggression or severe oppositional behaviors, sudden deterioration
in school performance, and sensory abnormalities. This could be attributed to symptoms
similar to those of autism spectrum disorder (ASD). ASD is a group of neurodevelopment
dysfunctions causing behavioral abnormalities in social, verbal, and non-verbal
communication (Huxley et al., 2017). The etiology of ASD is unknown but is
hypothesized to be the outcome of a combination of genetic, neurological, environmental,
and immunological factors (Huxley et al., 2017). In a study by Huxley et al., (2017),
researchers aimed to established functional interactions between the targets of autoantigens produced as a result of GAS, and genes linked to ASD, via genome wide
association studies. Huxley et al., (2017) discovered that there is a relationship between
immune and autoimmune responses caused by GAS infection associated with ASD.
Symptoms of Autism Spectrum Disorder (ASD) can include, but are not limited to,
•

Avoiding eye contact

•

Having little interest in other children or caretakers

•

Limited display of language

•

Being upset by minor changes in routine

Autism Spectrum Disorder can sometimes be detected as early as 18 months of age,
but more typically happens around the second year. Diagnosis by an expert at age two is
considered very reliable (CDC, 2021). Children with ASD can have difficulty making
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and maintaining friendships, difficulty understanding social expected norms, and can
have co-occurring conditions such as ADHD, OCD, anxiety, and/or depression. There is
no cure for ASD. The Food and Drug Administration has approved the use of risperidone
for treatment of ASD symptoms in children, and this treatment works best when
combined with therapy to maximize the child’s functioning and reducing the symptoms
of ASD (NIH, 2021). Huxley et al. (2017) states that further experimental research into
potential autoimmune etiologies of ASD is needed. Goncalves et al. (2018) states that
manifestations of ASD are considered to have neuroimmune etiology, and describes a
case study of a six-year-old male patient who was incorrectly diagnosed ASD but in fact
had PANDAS. The patient was treated with IVIG and reached complete remission of
symptoms (Goncalves et al., 2018).
Anxiety
Anxiety and separation anxiety are comorbid symptoms in the diagnostic criteria
of PANDAS. Anxiety is persistent or extreme fears that can happen in both adults and
children. When children do not outgrow the fears or when the fears persist and interfere
with daily life, children may have an anxiety disorder. Anxiety in children can include:
•

Separation anxiety

•

Phobias

•

Social Anxiety

•

Generalized Anxiety

•

Panic Disorders

Anxiety typically presents as fear and worry, but can also include rage, anger, and
irritability. Anxiety can be challenging to diagnose in children as it may be the result of
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other disorders or trauma. It is important for practitioners to investigate all possible
causes when diagnosing anxiety in children (CDC, 2021). Any child can develop anxiety,
but it is highly more likely in children who have biological disorders, experience stress or
trauma, maltreatment, or if the anxiety is hereditary from parents (CDC, 2021). Behavior
therapy and cognitive behavioral therapy are two of the widely used treatment plans for
children suffering with anxiety, in addition to eating a healthy diet, getting plenty of
sleep, and physical activity.
Dysgraphia and Academic Decline
A comorbid diagnostic symptom of PANDAS is academic decline. Dysgraphia is
a learning disorder in which the child’s writing skills are not where they are expected to
be given their age and cognitive level (Chung & Patel, 2015). Academic decline in
PANDAS patients can present as dramatic handwriting changes, decline in memory,
and/or decline in math skill. Dysgraphia can present on its own but can typically occur
with other neuropsychiatric issues (Chung & Patel, 2015). Dysgraphia can often go
misdiagnosed or incorrectly managed due to the lack of understanding of potential cause.
Chung and Patel (2015) state the importance of proper diagnosis and intervention from
family care providers.
Eating Restrictions
One of the three main criterion for PANDAS diagnosis includes acute and
dramatic onset of eating restrictions. This can include significant weight loss, fear of food
contamination, obsessions about healthy eating, and fear of eating (Calkin & Carandang,
2007). Anorexia is a severe psychiatric disorder. Tasaka et al. (2017) states that
childhood and adolescent onset of anorexia should be much more closely followed up on
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because of comorbid symptoms as well as long-term follow up needs. Anorexia nervosa
includes both the restricting subtype of eating disorder and the binge/purge subtype of
eating restriction. The most prevalent in childhood onset anorexia is the restricting
subtype (Tasaka et al., 2017).
PANDAS Diagnosis
Understanding the various other neuropsychiatric syndromes is important in the
understanding of PANDAS. In cases of PANDAS, the above listed neuropsychiatric
disorders are symptoms that develop as a result of basal ganglia inflammation and are not
stand-alone diseases. PANDAS. The aforementioned diseases have standards of care
implemented and are accepted by the medical community, while PANDAS is frequently
misdiagnosed. PANDAS requires a clinical diagnosis, meaning there is no laboratory test
that can diagnose PANDAS.
Clinical Diagnosis
Clinical diagnosis of PANDAS is defined by: presence of significant obsessions,
compulsions, and/or tics, abrupt onset of symptoms or a relapsing-remitting course of
symptom severity, pre-pubertal onset, association with streptococcal infection, and
association with other neuropsychiatric symptoms (Snider & Swedo, 2004). PANDAS
can present with a wide variety of neuropsychiatric symptoms, including abrupt onset of
OCD, extreme food restriction, tics, and accompanying symptoms, which can include:
•

Anxiety

•

Emotional lability and/or depression

•

Irritability, aggression, and/or oppositional behavior

•

Behavioral regression

39
•

Deterioration in academic performance

•

Sensory sensitivities

•

Motor movement abnormalities

•

Somatic symptoms, such as sleep disturbance or urinary frequency

(Pandas Network, 2021).
PANDAS is a clinical diagnosis in which doctors use the PANDAS Physicians
Network diagnostic flowchart to make a diagnosis (PPN, 2020). Cases of PANDAS can
be mild, moderate, to severe. In a mild case of PANDAS, symptoms are significant and
cause disruptions at home and/or school and occupy a few hours per day (PPN, 2020). In
moderate cases of PANDAS, symptoms are distressing to the child, interfere with daily
activities, and occupy 50-70% of time each day during waking hours (PPN, 2020). In
severe PANDAS cases, symptoms are incapacitating, life threatening, and/or occupy 71100% of time during waking hours (PPN, 2020).
Cunningham Panel
The Cunningham Panel was developed by Dr. Madeleine Cunningham and is
overseen by Moleculera Labs. According to the Moleculera Labs website, the
Cunningham Panel is a series of blood tests that can assist clinicians in diagnosing
infection-triggered autoimmune neuropsychiatric syndromes, such as Basal Ganglia
Encephalitis and PANS/PANDAS. PANDAS is a clinical diagnosis, but Cunningham
Panel test results can be supportive of a clinical diagnosis by providing evidence of an
underlying autoimmune issue which can also help guide treatment methods (Moleculera
Labs, 2021). The Cunningham Panel consists of five blood tests, including:
•

Anti-Dopamine D1 Receptor
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•

Anti-Dopamine D2L Receptor

•

Anti-Lysoganglioside-GM1

•

Anti-Tubulin

•

Calcium/calmodulin-dependent protein kinase II (CaMKII)

According to the Moleculera Labs website, four of the five blood tests measure the
levels of circulating autoantibodies in serum that are directed against and bind to, or
block, specific neuronal targets in the brain. Each of these autoantibodies have been
associated with the presence of various neurologic and/or psychiatric symptoms. When
autoantibodies bind to or block these targets, they can disrupt normal neuronal
functioning, resulting in the onset of neuropsychiatric symptoms. Elevated levels on one
or more of these tests indicate that a person’s neuropsychiatric symptoms may be due to a
treatable autoimmune disorder, rather than a classic neurologic or psychiatric illness. The
Cunningham Panel is considered a metabolic test; therefore, the laboratory results
represent the values at the time the patient’s blood was collected, which may vary over
time, with treatment, and in conjunction with the presence or absence of symptoms.
There is much controversy surrounding the effectiveness of the Cunningham
Panel (Hesselmark & Bejerot, 2019; Hesselmark & Bejerot, 2017; Shimasaki et al.,
2020). In a study by Shimasaki et al. (2020), the results of the Cunningham Panel were
able to correlate with neuropsychiatric symptom changes, while a study by Hesselmark
and Bejerot (2017) concluded that the use of the Cunningham Panel for PANDAS
diagnosis is not supported by evidence in their study. As the usefulness of the
Cunningham Panel remains inconclusive and controversial, PANDAS remains a disorder
that requires clinical diagnosis.
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Barriers to Diagnosis
LaRusso et al., (2022) discusses gaps in diagnosis and care due to logistics of
medical coverage thus compromising children’s health and development. LaRusso et al.,
(2022) states that patients with PANS/PANDAS often receive untimely care that is not
covered by insurance. LaRusso et al., (2022) concludes that the for-profit structure of the
healthcare system in the United States results in costly and lengthy paths to treatment and
diagnosis for PANS/PANDAS patients. LaRusso et al. (2022) states that insurance
coverage in the United States for PANS/PANDAS depends on legislation, advocacy,
clinical characteristics of each child, and how for-profit insurance companies react to an
increased demand for services. In addition, many practitioners do not acknowledge the
condition or offer effective treatments. LaRusso et al. (2022) concludes that the financial
motivations of insurance companies across modern health care systems imposes
restrictions that impede access to care for those suffering with PANS/PANDAS.
Therefore, untimely care, the time gap from PANS/PANDAS symptoms to diagnosis and
treatment is the result of the modern logistics that structure the medical and insurance
fields. The results of the study by LaRusso et al. (2022) demonstrate how modern
medicine and various facets of insurance coverage fail to protect families of children with
PANS/PANDAS against catastrophic expenses, and block care that would prevent
developmental disruptions and losses, associated suffering of child and family, and save
cost to the health care system.
PANDAS Treatment
Therapy and prescription drugs are typically recommended for the disorders that
present with PANDAS, such as OCD or anxiety. However, these treatments fail for
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children suffering from PANDAS as these treatments treat only the symptoms, not the
underlying cause, of the condition. Typically, cognitive behavior therapy and selective
serotonin reuptake inhibitors are the therapies to treat OCD (Sigra et al., 2018).
However, for a large portion of PANDAS sufferers these treatment methods are not
enough since they do not treat the underlying autoimmune disorder. In the study by
Prasad et al. (2021), researchers investigated which treatments would be most effective
and satisfactory for treating PANDAS, which includes treating the underlying
autoimmune disorder. Treatment for PANDAS focuses on eliminating the autoantibodies
from circulation (Platt et al., 2017). Swedo et al. (2017) states that in particularly severe
cases of PANDAS that do not respond to drug and behavioral therapy,
immunomodulating therapies individually or in combination with corticosteroids,
rituximab, intravenous immunoglobulin, plasmapheresis, and mycophenolate can be
used. However, this should be with caution, as Williams et al. (2016) notes that steroids
used to improve OCD symptoms can worsen tics.
Although further information is needed to distinguish brain changes brought on
by inflammation causes by the immune system, Cooperstock et al. (2017) compiled
information to help create more systematic, practitioner evidence-based criteria to both
diagnose and treat PANS/PANDAS. Cooperstock et al. (2017) uses information from
treating rheumatic fever, Sydenham chorea, and practitioner experience with
PANS/PANDAS. Leonard and Swedo (2001) use practitioner expertise and a literature
review to provide a proposed model of pathophysiology of PANDAS in order to guide
diagnosis and treatment. In studies by Prasad et al. (2021) and Calaprice et al. (2018),
subjects were most commonly treated with antibiotics (n=60, n=675). In the study by
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Prasad et al., (2021), tonsillectomy was the second most occurring treatment (n=50), then
intravenous immunoglobulin (IVIG) (n=24), then prescription Rituximab (n=9), steroids
(n=12) and plasma exchange (n=6). The study did not discuss what type of antibiotics
were used so no correlations on antibiotic brand efficacy could be established from this
study. In the study by Calaprice et al. (2018), different brands and doses of antibiotics
and IVIG were examined. In the study by Calaprice et al. (2018), no form of
psychotherapy was considered to be very effective.
In the study by Prasad et al. (2010), there was no significant difference found in
frequency of the 10 surveyed symptoms except for choreiform movement. There was a
significant time effect on the symptoms classified as obsessive compulsions, tics,
frequent urination, trouble sleeping, general anxiety, dysgraphia, aggressive behavior,
behavior regression, and intrusive thoughts. Regardless of treatment type, all parents
reported a decrease in symptoms within the course of the year after treatment. With the
exception of choreiform movements, there was a reduction in frequency of all symptoms
over the year after diagnosis, regardless of treatment type.
Symptom exacerbations, commonly known as flares, are common in
PANS/PANDAS patients and can be caused by upper respiratory infections, influenza,
mycoplasma pneumoniae, lyme, gastrointestinal infections, dental infections, enterovirus,
and allergies (Cooperstock et al., 2017). In a study by Latimer et al. (2015), symptom
exacerbations treated with corticosteroids tended to last 4 weeks less than symptom flares
not treated with corticosteroids.
Antibiotics
In rheumatic fever and Sydenham chorea, treatment involves long-term antibiotics
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to treat the infection as well as prophylactically prevent future infection. Treatment of
PANDAS typically begins with antibiotics, and involves long-term antibiotics used to
prevent recurrent infection. Cooperstock et al. (2017) provides a dosing chart with
recommendations on brands of antibiotics and what to use if there is allergic reaction.
This is an important part, as some antibiotics are found more useful in fighting
streptococcal infections and the ability to treat neuropsychiatric disorders as a result of
bacteria than others (Cooperstock et al., 2017). Cooperstock et al. (2017) notes that use of
antibiotics prophylactically in PANDAS patients does not have complete evidence, but
notes that the potential benefit could be the possibility of preventing neural injury from
future GAS infections. In a case study by Ayadin and Abali (2010), early antibiotic
treatment was useful in treatment of PANDAS. In a study by Demesh et al. (2015),
antibiotics alone improved children suffering with PANDAS from a baseline of 10, worst
severity, to a score of 8. In a study by Rea et al., (2021) nearly all children in the
retrospective study were treated with antibiotics (56 of 62 participants). However, this
same study concluded that antibiotics did not have a significant effect on improving tics
or OCD symptoms. In a study by Rea et al., (2021), antibiotics helped temporarily
reduce OCD and tics, but did not have long lasting effect. In a study by Calaprice et al.
(2018), the majority of participants (n=675) were treated with antibiotics, and it was
concluded that a treatment course of >30 days produced the best results with 52% of
participants reporting it was a very effective treatment.
Plasmapheresis and Intravenous Immunoglobulin
In a study by Perlmutter et al. (1999) children with severe, misguided immune
response to infection were treated with either plasma exchange, intravenous
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immunoglobulin (IVIG), or placebo. Perlmutter et al. (1999) studied if plasma exchange
or IVIG would be more effective than placebo at reducing the neuropsychiatric
symptoms. Twenty-nine children completed the trial. Ten children received plasma
exchange, nine children received IVIG, and 10 children received placebo. At one month
post treatment, the IVIG and plasma exchange groups showed significant improvement in
neuropsychiatric symptoms (Perlmutter et al., 1999). In a study by Calaprice et al. (2018),
plasmapheresis was reported as having a positive initial response (n=25), but did not
create long-lasting effect.
In a study by Kovacevic et al. (2015), IVIG was used as a therapeutic approach
for twelve children in a case study. All 12 children benefited from IVIG administration,
even when symptoms had been present for several years prior to treatment (Kovacevic et
al., 2015). In a retrospective study of therapeutic plasma exchange therapy by Latimer et
al. (2015), 78% of respondents had significant reduction in symptom severity. Many
immunotherapies such as plasmapheresis and IVIG can take weeks to months to show
effectiveness (Platt et al., 2017). In a study by Rea et al. (2021), intravenous
immunoglobulin was not an effective treatment for the OCD in PANDAS patients. In a
study by Calaprice et al. (2018), 193 participants had received IVIG treatment and
reported that it was at least somewhat effective as treatment, but for 18% of these
participants the effects were not sustained. Sigra et al. (2018) states that IVIG as a
treatment method remains inconclusive due to double-blind studies showing low support
of this treatment. In a study by Pavone et al. (2020), on the effectiveness of IVIG for
PANDAS, all patients were classified with extreme grade of PANDAS, a noticeable
improvement of symptoms was evident for at least one year in 47 out of the 55 patients,
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11 of these showed an evident symptoms remission in a single attempt, and the remaining
required a second administration to notice lasting symptom improvement.
Tonsillectomy and Adenoidectomy
Sigra et al. (2018) notes various studies using tonsillectomy and adenoidectomy
for treatment of PANDAS, but notes that observational studies only provide weak
evidence for tonsillectomy and/or adenoidectomy being weak for PANDAS treatment. A
study by Harabuchi and Takahara (2019) notes the tonsil-induced autoimmune and
inflammatory response regarding the tonsillar Th17 cells. Harabuchi and Takahara (2019)
were able to link the overactive Th17 tonsil cells to the autoimmune and inflammatory
markers due to a hyperimmune response. To date, there has not been a controlled case
study using tonsil/adenoidectomy as a treatment for PANDAS. Prasad et al. (2021) points
out these that even without antibiotic treatment, tonsillectomy and adenoidectomy alone
can show symptom improvement. In a case report by Alexander et al. (2011),
tonsillectomy was performed on a child with PANDAS and at one year follow up, the
patient had not suffered from recurrent streptococcal infection and the neuropsychiatric
symptoms had resolved completely. In another case study by Caletrio et al. (2008), a
case report of a nine-year-old who had received tonsillectomy had no further symptoms
after surgery. In a study by Demesh et al. (2015), children who underwent tonsillectomy
had improved at all measured periods post-surgery. Demesh et al. (2015) found that after
tonsillectomy, four out of nine children had complete recovery with tonsillectomy, and
five out of the nine reported a baseline score of three for their symptoms, with all of them
measuring 10, worst severity, prior to surgery.
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Corticosteroids
Sigra et al. (2018) notes that corticosteroids can be an effective treatment and can
reduce the length of symptom exacerbations. In a study by Brown et al. (2017), flares
treated with corticosteroids typically lasted 4 weeks less than the 12.2 weeks without
corticosteroid use (Sigra et al., 2018). Brown et al. (2017) concludes that non-steroidal
anti-inflammatory drugs given prophylactically at flare onset may shorten the
neuropsychiatric symptom duration during a flare. Several case reports exist on
PANS/PANDAS treatment using corticosteroids, with some noting they are very
effective and others not effective due to increase in negative side effects (Sigra et al.,
2018). Since PANDAS serves as a forme fruste of SC, similar treatments may be
effective. A study by Fusco and Spagnoli (2018) found that corticosteroids were effective
in both short and long-term treatment of SC. A study by Favaretto et al. (2020) concluded
that corticosteroid treatment was effective for SC. Corticosteroids are typically used in
combination with other therapies, such as IVIG or antibiotics. Lack of double-blinded
placebo-controlled studies makes corticosteroid use in PANDAS treatment inconclusive
(Brown et al., 2017; Spartz et al., 2017). A study by Calaprice et al. (2018) concludes that
steroid therapy, including over the counter anti-inflammatories, was at least somewhat
effective for the majority of participants.
Psychotropic Drugs and Psychotherapy
Members of the PANS/PANDAS research consortium shared their clinical
experiences to develop treatment guidance for psychotropic drugs and psychotherapy
interventions in PANS/PANDAS (Thienemann et al., 2017). In a study by Rea et al.
(2021), 33 of 62 participants had received cognitive behavioral therapy (CBT) techniques
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that did show a significant improvement on OCD symptom severity, but did not have
significant improvement on tics. Rea et al. (2021) concluded that symptomatic therapy
such as haloperidol, risperidone, aripiprazole, clozapine, methylphenidate chloridrate,
and pimozide were administered in 15 of 62 participants but the therapies did not have
significant effect on tics or neuropsychiatric symptoms. In a study by Calaprice et al.
(2018), psychotropic medications, most commonly SSRIs, were reported as having been
used but reported as ineffective. The study by Calaprice et al. (2018) also concluded that
CBT was reported to at least be somewhat effective to those treated with this method.
Thienemann et al. (2017) states that the timing of CBT is important, as during particular
symptom flares the child may be unable to fully participate due to PANDAS symptoms,
but the sooner the intervention begins the more likely it will be helpful. Unlike other
conclusions, Wilbur et al. (2019) gives the recommendation that children presenting with
PANS/PANDAS should be treated with psychotropic medication and will be expected to
show improvement similar to that of children receiving psychotropic medication without
PANS/PANDAS. Thienemann et al. (2017) concluded that until further research has been
conducted on PANS/PANDAS specific psychiatric interventions, practitioners must rely
on treating PANS/PANDAS patients with standards of care used for the various
symptoms in non-PANS/PANDAS patients.
Remission
Felson (2011) describes remission as a state of being, and as the absence of
disease activity. In other diseases, such as rheumatoid arthritis, absence of disease
activity is what some would consider an unattainable goal. Felson (2011) states that
remission is more generally operationalized as either complete absence of disease activity
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or a level of disease activity that is so low it is no longer troublesome to the patient.
Future research is needed to better understand the aim of remission in PANDAS, how to
attain remission, and a clear definition of remission in PANDAS such as complete
remission or complete remission on treatment, and what treatments, if needed, can be
used for remission maintenance.
Remission in other Autoimmune Diseases
Systemic Lupus Erythematosus (SLE) and Rheumatoid Arthritis (RA) are both
autoimmune inflammatory diseases. Remission is typically the ultimate goal in any
disease, but various studies take different approaches to the definition of remission. In a
study on remission experiences in SLE, Wilhelm et al. (2021) describes four different
definitions of remission, including clinical remission, complete remission, clinical
remission on treatment, and complete remission on treatment. Like PANDAS, SLE often
follows a relapsing-remitting pattern. The study by Wilhelm et al. (2021) found that
achieving remission was frequent, but durable remission was rare. In SLE, the median
duration of remission for all definitions of remission was only 3 months (Wilhelm et al.,
2021). According to Doria et al. (2016), it is possible that remission may not be a suitable
target for some diseases, as in the case of SLE.
Another issue with the concept of remission is how to manage patients once
remission is achieved. According to Gul et al. (2021), medical advancements have led to
more promising outcomes of disease remission in RA; however, there is little guidance
on how to manage patients once remission is achieved. In a study by Wilhelm et al.
(2016) examining remission of SLE, the median time to remission varied based on the
definition of remission. Using the definition of clinical remission, the median time to
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reach remission was 8.7 years (Wilhelm et al., 2021). Using the definition of complete
remission, the median time to reach remission was 11.0 years (Wilhelm et al., 2021).
Using the definition of clinical remission on treatment, the median time to reach
remission was 1.8 years (Wilhelm et al., 2021). Using the definition of complete
remission on treatment, the median time was 3.1 years (Wilhelm et al., 2021). The
median time the remission was sustained was similar with all four definitions at 105 days
(Wilhelm et al., 2021). This study not only sheds light on the need for clear definitions of
remission, but also the importance of further studies related to remission management
and treatment options.
Remission Experiences for Children and Families
Studies of other childhood illness offer guidance related to family and child
experiences in dealing with disease and remission. Reinfjell et al. (2009) conducted a
study on children in remission from leukemia regarding their mental health, psychosocial
adjustment, and parental functioning. Reinfjell et al. (2009) concluded that all children in
the study (N=40) were children in remission from leukemia and all showed significantly
more problematic issues regarding mental health and psychosocial adjustment, according
to their parents’ perception, compared to healthy controls. The length of treatment for
childhood leukemia can vary but is an average of 2.5 years. This time period can create
an enormous amount of stress during treatments and can isolate children away from their
peers for long periods of time. A study by Drotar (1997) states that parental functioning is
one of the strongest contributors to adjustment in children with chronic health conditions.
According to Reinfjell et al. (2009) and Maurice-Stam et al. (2008), emotional distress
among parents remains heightened compared to healthy controls for one year after end of
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treatment, but then begins to decrease over time. Reinfjell et al. (2009) states that a
significant number of parents will still suffer from clinical distress five years posttreatment. Another element of reaching remission during childhood is the discussions
parents must have with their child about the possibility of the disease returning. Murphy
et al. (2020) studied how mothers and children discuss possible cancer recurrence in
childhood cancer survivors. Murphy et al. (2020) examined discussions mothers have
with their children related to fears of cancer recurrence. Examining these discussions can
help guide predictors and communication cues for families to support them through fear
of recurrence conversations. These studies shed light on the importance of adequate
rehabilitation for children in remission.
In a study by Erbis et al. (2018) the daily life struggles for children, adolescents,
and adults living with autoimmune diseases was investigated. Erbis et al. (2018)
concluded that unmet needs of those living with autoimmune diseases impacts all areas of
life, with the most relevant unmet needs happening within the school and health care
systems. Rea et al. (2021) noted that worsening school performance, increased anxiety,
irritability, and aggressivity all increase with symptom exacerbations. In a study by Vlist
et al. (2019) researchers sought to understand participation in childhood in those with
chronic disease. Vlist et al. (2019) found that children with chronic disease learn to
carefully weigh participation against their current and/or future needs and assess the risk
versus benefit of their choices and chronic condition needs. Vlist et al. (2019) states that
children view participation as more than just engaging in an activity, but having a sense
of belonging and the ability to influence social interactions and keep up with their peers.
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Tona et al. (2017) conducted a study to determine what problems arise in terms of
occupation, body functions, and performance skills during PANS or PANDAS symptom
exacerbations. This study concluded that children present with pervasive occupational
performance needs during exacerbation periods and that children may benefit from
accommodations to maximize function during these periods (Tona et al., 2017).
Frankovich et al. (2019) studied PANS symptom severity and its relation to caregiver
burden. Frankovich et al. (2019) concluded that PANS caregivers suffer high caregiver
burden, and the severity of the PANS syndrome predicts increased caregiver burden.
Erbis et al. (2018) recommends that it is an urgent need to increase societal knowledge
and empower patients as well as create supportive environments at school and work to
help ensure successful participation of those with autoimmune diseases have their
psychosocial needs met. Maurice-Stam et al. (2008) states that the time when a child’s
treatment ends and remission begins is typically a difficult and anxious time for both the
minor patient and their parents, as during this time the social and emotional support from
other’s decreases but the family is just beginning their journey in coming to terms of
what has happened. Murphy et al. (2020) states that 62% of adolescent and young adult
cancer survivors reported clinically significant levels of fears that their cancer will return.
Murphy et al. (2020) states that the fear of cancer recurrence is associated with a range of
difficulties that can include impaired psychological functioning, poor health-related
quality of life, greater healthcare utilization, and maladaptive health behaviors.
Ringer and Roll-Pettersson (2022) discuss some feelings of parent experiences
when dealing with a child with PANS/PANDAS. Themes that emerged from the study by
Ringer and Roll-Pettersson (20220) included categories such as:
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•

he/she was a completely different child

•

their suffering is unbearable

•

unable to parent their other children

•

continuous and clear care plans are hard to get

•

parents are blamed

•

trying to make up for lost childhood

Ringer and Roll-Pettersson (2022) state that parents of children with relapsing and
remitting symptoms often tried to compensate for lost time and create enjoyable moments
with the child when he/she was not in a symptom flare as a way to give back the lost
childhood and attempt to compensate for their suffering. However, Ringer and RollPettersson (2022) distinguish children that have a static symptom course, rather than
remitting, are unable to have these moments as parents indicate they are not able to live
normally for even small amounts of time due to always dealing with the illness.
PANDAS Remission
PANDAS is considered to have a relapsing and remitting pattern, where exposure
to bacteria or virus can induce symptoms, and symptoms wax and wane over time, known
as symptom flares or symptom exacerbations. Cooperstock et al. (2017) states that
symptom exacerbations are common in PANS/PANDAS patients and can be caused by
upper respiratory infections, influenza, mycoplasma pneumoniae, lyme, gastrointestinal
infections, dental infections, enterovirus, and allergies. There is little literature related to
symptom flares, their duration, and what to do to manage them. In a study by Leon et al.
(2018), at follow-up, 29 of the 33 participants were experiencing no or only subclinical
OCD symptoms. Of the remaining 4 with clinically significant OCD symptoms, one
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child was currently experiencing a symptom exacerbation at the time of follow-up, one
child had discontinued all treatments before all symptoms had resolved, and two children
had persistent OCD and remained in treatment (Leon et al., 2018). In a study by Colvin et
al. (2021), the cognitive, graphomotor, and psychosocial challenges PANDAS patients
faced were ongoing and significant academic difficulty and emotional, behavioral, and
social concerns remained after symptom resolution. In a retrospective study of 40
patients, Latimer et al. (2015) concluded that improvement with therapeutic plasma
exchange was not associated with the duration of illness. This finding needs further
research, as this could imply that the damage inflicted from PANDAS is able to be
treated regardless of how long the symptoms were present. In a study by Gruijter et al.
(2021), a bidirectional relationship between puberty and autoimmune rheumatic disease
was found. In a case study by Cross et al. (2021), the researchers conclude that after a
span of 31 months of illness and treatment with antimicrobials and IVIG, the patient
reached complete remission.
When children experience PANDAS flares, they often require individualized
education plans at school in order to accommodate their PANDAS symptoms. In a study
by Latimer et al. (2015), symptom exacerbations treated with corticosteroids tended to
last 4 weeks less than symptom flares not treated with corticosteroids, which tended to
last 12 weeks. In a study by Shimasaki et al. (2020), the results of the Cunningham Panel
were able to correlate with neuropsychiatric symptom changes during symptom
exacerbations. A study by Lepri et al. (2019) concluded that infection-related relapses
were observed in 167 out of 371 participants long-term. The Pandas Physicians Network
recommends, even in severe cases, that after treatment has been successful, a specialist is

55
needed in order to manage flares. Mohammad and Dale (2018) find in PANS/PANDAS
patients, there is a risk of relapse in the majority of patients. It is not clear if symptom
exacerbation management is life-long or if remission includes complete symptom
recovery with no further exacerbations. Defining remission in PANDAS could be helpful
in the future.
Ringer and Roll-Pettersson (2022) describe the effect of PANS/PANDAS on
families by exploring parental stress. Ringer and Roll-Pettersson (2022) identified five
categories of parents’ experiences related to the stress of dealing with a child with
PANS/PANDAS, including, “being effected by the symptoms, experiencing the
symptoms over and over again, having no control, obtaining medical treatment being
challenging, and managing problems.” The study by Ringer and Roll-Pettersson (2022)
highlights the effect of PANDAS on the family system and is a gateway to future
research on how to minimize family issues related to the disorder.
Long-Term Outcomes
Few studies shed light on the long-term outcomes of children with PANDAS.
Although there is a consensus on standard of treatment, long-term outcomes of these
treatment methods are unknown. In a study by Leon et al. (2018), 33 children with
PANDAS participated in follow-up interviews after treatment. After an average of 3.3
years after baseline evaluation, 88% of participants were in complete or nearly complete
remission (Leon et al., 2018). However, most children, 72%, had at least one symptom
exacerbation of PANDAS during the three-year follow up period. These exacerbations
were typically less severe and generally short-lived compared to the baseline episode
(Leon et al., 2018). During symptom exacerbations, a variety of treatments were used,
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including all or combinations of antibiotics, immunomodulatory therapies, and cognitive
behavioral therapies (Leon et al., 2018). At the follow-up, 29 of the 33 participants were
experiencing no or only subclinical OCD symptoms. Of the remaining 4 with clinically
significant OCD symptoms, one child was currently experiencing a symptom
exacerbation at the time of follow-up, one child had discontinued all treatments before all
symptoms had resolved, and two children had persistent OCD and remained in treatment
(Leon et al., 2018). In a study by Colvin et al. (2021), the cognitive, graphomotor, and
psychosocial challenges PANDAS patients face were ongoing and significant academic
difficulty and emotional, behavioral, and social concerns remained after symptom
resolution.
A study by Lepri et al. (2019) concluded that infection-related relapses were
observed in 167 out of 371 participants long-term. Mohammad and Dale (2018)
concluded that the majority of PANS/PANDAS patients will have relapse, persistent
OCD, and tics. Mohammad and Dale (2018) also conclude that in PANS/PANDAS
patients the speed of recovery is typically rapid, whereas in other immune-mediated
movement disorders, such as SC, can take months to years.
Gromark et al. (2022) concluded that complete remission was rare (n=34),
however, the majority of children did improve over a 3-year follow-up period. Gromark
et al. (2022) also found that a minority of patients that displayed a chronicstatic/progressive course that required additional treatments. The operationalized
definitions of flare and clinical course were able to distinguish the chronic and nonchronic groups of participants. This information will be useful as a basis in future studies
related to treatment and prognostic guidelines.
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The aforementioned studies create a starting point for this study. Very little is
known about the remission of PANDAS. Based on these studies, it seems the factors in
PANDAS remission, as well as what typical remission and subsequent symptom
exacerbations looks like, can vary or remains unexplained. There are also many factors of
remission in PANDAS that have yet to be explained, such as lasting psychosocial issues
of the child and parents and remission management plans. This study will take a
qualitative approach to parents’ perceptions of factors of remission in PANDAS, that
could lead to future research detailing what treatments lead to remission and how to best
treat symptom exacerbations, should they continue into remission.
Biblical Foundations of the Study
As the aim of this study was to gain parents’ perceptions of PANDAS remission,
this study provides hope for parents currently battling PANDAS and provides them with
information to help them persevere. A study by Maurice-Stam et al. (2008) on emotional
functioning of families during remission of pediatric cancer found that parents who were
optimistic about the further course of their child’s disease reported fewer emotional
problems, evidence of the importance of keeping hope and faith in mind when dealing
with the illness of a child. In 1 Thessalonians 1:3, Paul is addressing the church and
expressing his gratitude in their response to the gospel. He mentions their work of faith,
labor of love, and steadfast hope. God’s grace had saved them when they put their faith in
Christ instead of endeavoring to be saved by their own efforts, and the same grace had
produced in them the good works God had intended to produce in their lives. 1
Thessalonians 1:3 says, “We remember before our God and Father your work produced
by faith, your labor prompted by love, and your endurance inspired by hope in our Lord
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Jesus Christ.” This scripture could be a direct example of the faith, hope, and love
PANDAS parents rely on in pursuit of care and healing for their children. As parents
faithfully hope for remission for their children, Romans 5:5 says, “And hope does not put
us to shame, because God’s love has been poured out into our hearts through the Holy
Spirit, who has been given to us.” As doctors and insurance agencies and other facets of
the medical system can cause disruption and delay for medical healing, this is man’s
word, not the Word of God. In Psalm 3:2-6 the Bible says, “Many are saying of me, ‘God
will not deliver him,’ But you, Lord, are a shield around me, my glory, the One who lifts
my head high. I call out to the Lord and he answers me from his holy mountain. I lie
down and sleep, I wake again, because the Lord sustains me. I will not fear though tens of
thousands assail me on every side.” Both parents and the children suffering with
PANDAS must remain steadfast in their hope, faith, and love.
Biblical Worldviews of the Study
Using Johnson’s (2010) Five Views, and Wolter’s (2005) Creation Regained, the
transformational worldview approach of this study operates under the premise that God
gave scientists the minds that are able to comprehend and do great scientific work, and
that it is their duty to carry out ethical science morally. Johnson (2010, p. 225) concludes
by saying that the Transformational View is not about trying to make two separate
disciplines, as in faith and science, relate. Rather, the Transformational View is the study
of psychology through faith and contemplating God in the process. The researcher
approached this study with the goal of discovery and helping others as told to do in 2
Timothy 3:17, “That the man of God may be competent, equipped for every good work.”
The researcher approached the study of PANDAS as a way to provide testimony for
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drawing closer to God. In doing so, the researcher aims to be a servant to child
development, families, youth mental health, and families struggling with pediatric illness
such as PANDAS. The researcher aims to provide sound research and define areas for
future research for PANDAS families, as 1 Samuel 15:13, “The Lord bless you, I have
carried out the Lord’s instructions.”
Biblical References of the Study
The story of Elisha and Naaman in 2 Kings discusses how illness does not
discriminate between people. Naaman, the commander of the Syrian army, fell ill with
leprosy. Naaman’s pride nearly kept him from receiving healing. This is similar to
parents of PANDAS patients, as many will try to do all within their power to help their
children. Parents of sick children plead to God for answers and healing, and must learn to
be patient and accept the path God has laid out for them. This does not mean parents
cannot read and equip themselves with the science that is available related to PANDAS,
as God created the scientists that study PANDAS. Proverbs 24:14 states, “Know also that
wisdom is like honey for you: If you find it, there is a future hope for you, and your hope
will not be cut off.” This study on remission will provide education and hope for parents
of children with PANDAS. With the wisdom from scientific literature and the
foundations of the Bible, parents on the path to remission for their children will have the
understanding that like all things in life, PANDAS exacerbations are a season.
Ecclesiastes 3:1-8 explains how everything in life has a season. In the season of
PANDAS, and hoping for remission, the Bible says in Isaiah 40:31, “But those who hope
in the Lord will renew their strength. They will soar on wings like eagles; they will run
and not grow weary; they will walk and not be faint.”
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In Jeremiah, Israel was exiled for disobedience. A false prophet had told the
people of Israel that God would deliver them within two years’ time. Jeremiah delivers
the news that Israel will be in exile for seventy years. This is not what the people of Israel
wanted to hear. God wants the people to know that he still has a plan for them, even when
they are facing a dark situation. The people must hold on to hope that God is not finished
with them. Romans 12:12 says, “Be joyful in hope, patient in affliction, and faithful in
prayer.” As time drags on, such as the seventy years in Israel or waiting on PANDAS
healing, parents can be reminded of hope in the face of trouble, as the Bible tells in
Romans 8:24-25, “Who hopes for what they already have? But if we hope for what we do
not yet have, we wait for it patiently.” This tells PANDAS parents to wait patiently for
remission and healing for their children. Isaiah 43:18-19 says, “Forget the former things;
do not dwell on the past. See, I am doing a new thing! Now it springs up; do you not
perceive it? I am making a way in the wilderness and streams in the wasteland.” Hope
requires the belief from PANDAS parents that God provides and cares for their children,
and will keep moving toward remission. The Bible has many stories related to people
persevering through hard times with hope and faith in God. The Scripture can encourage
PANDAS parents to keep asking, seeking, and knocking using scientific foundations and
the hope that God’s deliverance from PANDAS is imminent. As PANDAS families
endure the wax and wane symptom exacerbations and various treatments, the Bible tells
the story of Paul and persevering through troubles for eternal glory. 2 Corinthians 4:1618 states, “Therefore we do not lose heart. Though outwardly we are wasting away, yet
inwardly we are being renewed day by day. For our light and momentary troubles are
achieving for us an eternal glory that far outweighs them all. So, we fix our eyes not on
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what is seen, but on what is unseen, since what is seen is temporary, but what is unseen is
eternal.” Paul also discusses how he is not perfect, but has the goal of living a Christ-like
life. In Philippians 3:12-16 Paul is discussing being made perfect in the Lord and states,
“Not that I have already obtained all this, or have already arrived at my goal, but I press
on to take hold of that for which Christ Jesus took hold of me. Brothers and sisters, I do
not consider myself yet to have taken hold of it. But one thing I do: Forgetting what is
behind and straining toward what is ahead. I press on toward the goal to win the prize for
which God has called me heavenward in Christ Jesus.” This Scripture illustrates the
importance of seeking scientific assistance for PANDAS and doing all that a parent is
capable of for their child, but not losing hope, because science is not the final answer in
PANDAS healing, but God providing healing. Isaiah 65:24 says, “I will answer them
before they even call to me. While they are still talking about their needs, I will go ahead
and answer their prayers!”
The Bible states many times to keep hope and faith, and rest in God’s power and
glory. Galatians 5:22-23 says, “But the fruit of the Spirit is love, joy, peace, forbearance,
kindness, goodness, faithfulness, gentleness and self-control.” The Bible mentions the
word “rest” 275 times. The Bible calls people to be at peace and rest and believe God’s
promises. In the book of John, Mary and Martha tell Jesus about Lazarus. The Bible
states in John 11:6 that Jesus knew Lazarus was sick, but he loved Mary and Martha so
he stayed where he was for two more days. When Jesus gets to Lazarus days later, Jesus
tells them as stated in John 11:40, “Did I not tell you if you would only believe you
would see the glory of God?” The Bible is teaching that God loves His people enough not
to deliver them in their time, but in His time. The Bible promises us that all things will
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work together for good, to rest, and to have faith. Matthew 17:20 says, “Truly I tell you,
if you have faith as small as a mustard seed, you can say to this mountain, ‘Move from
here to there,’ and it will move. Nothing will be impossible for you.” To believe God’s
promises, families need to rest in faith for healing from PANDAS. If parents try to make
things happen in their time and not God’s it will lead only to frustration and resentment.
God does not call His people to be frustrated, he calls them to rest and have faith. Faith
for PANDAS families is knowing God’s promises before they are evident in the
circumstance. Parents love their children and want whole healing for them. Parents rely
and believe in the promise in Philippians 1:6, “Being confident of this, that He who
began a good work in you will carry it on to completion.”
Biblical Summary
During times of uncertainty when dealing with a PANDAS diagnosis of a child,
parents must equip themselves with the armor of God to persevere through the disease to
reach remission. In 2 Corinthians, Paul prays to have the thorn from his flesh removed on
three different occasions, but God does not remove it and explains that it is beneficial to
him. 2 Corinthians 12:7-9 states, “To keep me from becoming conceited because of these
surpassingly great revelations, there was given me a thorn in my flesh, a messenger of
Satan, to torment me. Three times I pleaded with the Lord to take it away from me. But
he said to me, ‘My grace is sufficient for you, for my power is made perfect in
weakness.’ Therefore, I will boast all the more gladly about my weaknesses, so that
Christ's power may rest on me.” Parents must keep in mind in dealing with this illness
that His power is made perfect in our weakness, such as the weakness of a child with an
illness. Parents have to persevere for the sake of their children. John 20:29 says, “Blessed
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are those who have not seen and yet believed.” Although parents are rightfully
discouraged, they must remember to put their faith in God and wait for His timing for
healing. Hebrews 12:1 says, “And let us run with perseverance the race marked out for
us.”
Summary
In a study by Leon et al. (2018), at follow-up, 29 of the 33 participants were
experiencing no or only subclinical OCD symptoms. Of the remaining 4 with clinically
significant OCD symptoms, one child was currently experiencing a symptom
exacerbation at the time of follow-up, one child had discontinued all treatments before all
symptoms had resolved, and two children had persistent OCD and remained in treatment
(Leon et al., 2018). In a study by Colvin et al. (2021) the cognitive, graphomotor, and
psychosocial challenges PANDAS patients face were ongoing and significant academic
difficulty and emotional, behavioral, and social concerns remained after symptom
resolution.
In a retrospective study of 40 patients, Latimer et al. (2015) concluded that
improvement with therapeutic plasma exchange was not associated with the duration of
illness. In a study by Gruijter et al. (2021), a bidirectional relationship between puberty
and autoimmune rheumatic disease was found. In a case study by Cross et al. (2021), the
researchers conclude that after a span of 31 months of illness and treatment with
antimicrobials and IVIG, the patient reached complete remission. A study by Gromark et
al. (2021) found that although complete remission was rare, 85% of patients had greatly
improved at 2 to 5 years follow-up. The aforementioned studies create a starting point for
this study. Very little is known about the remission of PANDAS. This study will take a
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qualitative approach to factors of remission in PANDAS, that could lead to future
research detailing what treatments lead to remission and reduction of symptom
exacerbations.
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CHAPTER 3: RESEARCH METHOD
Overview
The purpose of this qualitative phenomenological case study was to explore
parents’ perceptions of factors contributing to the remission of PANDAS. In a
retrospective study of 40 patients, Latimer et al. (2015) concluded that improvement with
therapeutic plasma exchange was not associated with the duration of illness. In a study by
Gruijter et al. (2021) a bidirectional relationship between puberty and autoimmune
rheumatic disease was found. In a case study by Cross et al. (2021), the researchers
conclude that after a span of 31 months of illness and treatment with antimicrobials and
IVIG, the patient reached complete remission. A study by Lepri et al. (2019) concluded
that infection-related relapses were observed in 167 out of 371 participants long-term.
Mohammad and Dale (2018) concluded that the majority of PANS/PANDAS patients
will have relapse, persistent OCD, and tics. Mohammad and Dale (2018) also conclude
that in PANS/PANDAS patients the speed of recovery is typically rapid, whereas in other
immune-mediated movement disorders, such as SC, can take months to years. Very little
is known about the remission of PANDAS. Based on the studies by Latimer et al. (2015),
Gruijter et al. (2021), Cross et al. (2021), Lepri et al. (2019), and Mohammad and Dale
(2018), it seems the factors in PANDAS remission, as well as what typical remission and
subsequent symptom exacerbations entails, is not clearly defined.
This study took a qualitative approach to parents’ perceptions of factors in
remission, in order to understand the lived experiences of PANDAS families and the
journey to remission. This study investigated parent’s perceptions on factors of remission
in PANDAS. This study analyzed patterns related to age, severity of illness, treatment
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methods, and symptom exacerbations as factors of remission in PANDAS. Studies
related to long-term outcomes of PANDAS, effective treatments, and remission
management are scarce and/or inconclusive. This study aimed to discover patterns
leading to remission and can guide future research on exploration of factors of remission
in PANDAS and will serve as a road map for parents of children recently diagnosed with
PANDAS.
Purpose of the Study
The purpose of this qualitative phenomenological case study was to explore
parents’ perceptions of factors contributing to the remission of PANDAS. This study
aimed to discover patterns in reaching PANDAS remission related to age, severity of
illness, treatment methods, and symptom exacerbations. The study used a 16-question
original survey on Qualtrics related to parents’ perceptions of factors of remission in
PANDAS. Findings from this study can be used in future research to discover cause and
effect relationships between treatment methods, age, and symptom severity to better
guide treatment protocols in the future.
Research Questions
RQ1: According to parents’ perceptions, which treatment is most effective in
achieving remission?
RQ2: According to parents’ perceptions, how long does achieving remission take?
RQ3: According to parents’ perceptions, is length of PANDAS illness prior to
receiving diagnosis and treatment related to achieving remission?
RQ4: According to parents’ perceptions, is severity of PANDAS symptoms
related to achieving remission?
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RQ5: According to parents’ perceptions, is age of PANDAS patient at symptom
onset related to achieving remission?
RQ6: According to parents’ perceptions, is presence of puberty related to
PANDAS symptoms?
RQ7: According to parents’ perceptions, are symptom flares experienced after
achieving remission?
RQ8: According to parents’ perceptions, is gender related to presence of
remission?
RQ9: According to parents’ perceptions, what is the most effective treatment for
remission maintenance?
Research Design
The goal of this study was to better understand the factors involved in remission
for PANDAS patients according to parents’ perceptions. Therefore, this research was best
suited for a qualitative study to allow for the understanding of the lived experience of
PANDAS families remission experiences rather than testing cause and effect
relationships. According to Creswell and Poth (2018, p. 8), qualitative research begins
with an assumption and uses interpretive and theoretical frameworks to inform the study
to address research problems by addressing a group with a human problem, in this case,
PANDAS remission. In order to study the problem, the researcher takes a qualitative
approach in order to find patterns or themes. The findings of the study include a complex
description and interpretation of the problem and its contribution to the literature
(Cresswell & Poth, 2018, p. 8). Mack et al. (2005) describes qualitative research as
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seeking to explore phenomena, using more flexible instruments, in order to describe and
explain relationships.
As a methodological approach, phenomenology allows for the examination of the
lived experience of the journey to remission in PANDAS. According to Cresswell and
Poth (2018) phenomenology has an emphasis on a single concept or idea; in this study,
this concept is remission. This study aims to understand parents’ perceptions of factors of
remission from parents of children diagnosed with PANDAS. This study aimed to
understand parents’ perceptions of remission from parents of children diagnosed with
PANDAS.
Data in this study were analyzed using a transcendental phenomenological
approach. Creswell and Poth (2018) describe phenomenology as describing the personal
experiences with the phenomenon under study. The phenomenon seeking to be better
understood in this study is the process of remission in PANDAS. Phenomenology creates
a description of what the participants in the study experienced, how the experience
happened, and aims to capture the essence of the phenomenon (Creswell & Poth, 2018, p.
201). By using a transcendental phenomenological approach, the researcher is able to find
themes and patterns in the phenomena under investigation. In a phenomenological case
study, reality needs to be interpreted. In a phenomenological approach, the researcher is
able to use epoche, or bracketing, to account for their own experience. By using epoche,
the researcher acknowledges and discusses their experience with the phenomena, but puts
that aside in order to try to better understand the experience of the participants (Cresswell
& Poth, 2018). Hardy (2018) describes etic as the outsider’s perspective, and it is
achieved by examining and interpreting data through a psychological lens in which the
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researcher finds helpful to bring an understanding of the research questions. Hardy
(2018) describes emic as the insider’s perspective, which takes a pragmatic approach to
help the researcher shape the varied nature of the explanations from the study. The
pragmatism paradigm asserts that the best method is one that solves problems. The
transcendental phenomenological approach allows for flexibility in the study so that the
researcher can modify guidelines to fit their research objectives (Creswell & Poth, 2018).
Case Study Design
This study is classified as a multiple series case study. This study used a priori
critical case sampling, which allowed for logical generalizations of remission experiences
and provided maximum application of information to other cases of PANDAS families
(Cresswell & Poth, 2018, p. 159). It was difficult to estimate an appropriate sample size
of remission experiences since there is limited literature related to long-term PANDAS
outcomes (Kovacevic et al., 2015; Latimer et al., 2015; Leon et al., 2018). In previous
studies regarding treatment outcomes, researchers have conducted single case studies or
have sample sizes of 40 participants or less (Brown et al., 2017; Calaprice et al., 2018;
Demesh et al., 2015; Kovacevic et al., 2015; Latimer et al., 2015; Leon et al., 2018).
Calaprice et al. (2018) is the only large-scale treatment outcome study that could be
located. Calaprice et al. (2018) conducted a retrospective study of 698 participants and
asked questions related to treatment experiences. The study by Calaprice et al. (2018) is
similar to this study proposal; however, the study by Calaprice et al. (2018) includes all
PANS diagnoses and is not specific to only PANDAS.
There are two types of phenomenology, Hermeneutic and transcendental
(Cresswell & Poth, 2018). This study used transcendental phenomenology, which is
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oriented toward the description of the experience of the participants. The researcher uses
the concept of epoche in order set aside their own experiences. The researcher bracketed
herself out of the study by discussing her own relationship with PANDAS which allowed
for a better understanding of participant experiences.
This study used critical case sampling, which allows for logical generalizations of
remission experiences and provides maximum application of information to other cases
of PANDAS families who have not yet reached remission (Cresswell & Poth, 2018, p.
159). This study took a direct interpretation approach, which allowed the researcher to
look at the instance of remission in PANDAS and extrapolate the data in more
meaningful ways (Cresswell & Poth, 2018, p. 206). This study used Wolcott’s (1994)
approach to validation with the premise that in this study validity of a survey tool would
neither guide nor inform the qualitative research, as the goal was to gain a better
understanding of PANDAS remission (Cresswell & Poth, 2018, p. 255). Wolcott (1994)
states that understanding is better than validity, and the goal of this study was to gain
better understanding of PANDAS remission (Cresswell & Poth, 2018, p. 255).
The sampling process and emergence of patterns in data analysis allows
generalizations of information that can be used as building blocks in future research.
This study included 16 survey questions on Qualtrics to be answered by parents of
children diagnosed with PANDAS (See Appendix A).
Participants
Participants were at least 18 years old, with English as their primary language,
and the parent of a child diagnosed with PANDAS from a medical doctor. Parents of
children diagnosed with PANDAS were identified through Facebook PANDAS support
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groups and the National Institute of Mental Health Outreach Partnership Program Aspire
PANS/PANDAS newsletter. Exclusion criteria included lack of PANDAS diagnosis from
a medical doctor, being under 18 years of age, or not being the parent of a child with
PANDAS. The Facebook recruitment took place using a social media invitation to
participate in a 16 question Qualtrics survey (See Appendix B). Following the link on the
Facebook post redirected participants to the Qualtrics survey introduction and informed
consent (See Appendix D). The Aspire newsletter recruitment took place using an
invitation to participate in a 16 question Qualtrics survey (See Appendix B). Following a
link in their email newsletter redirected participants to the Qualtrics survey introduction
and informed consent (See Appendix D).
Facebook and Aspire newsletter administrators were contacted upon IRB
approval of this study in order to gain permission for group participation in the study.
Administrators were sent a message by the researcher upon IRB approval (See Appendix
C). Once approval was granted, the group administrator either published the survey
recruitment on their group page or granted the researcher permission to post the
recruitment on the Facebook page or newsletter (See Appendix B).
The first page of the survey was the informed consent and introduction (See
Appendix D). After providing consent in the first three questions, the participant was
directed into the survey (See Appendix A). The Facebook group permissions were
obtained from PANDAS-Pediatric Autoimmune Neuropsychiatric Disorder Associated
w/Strep, PANDAS Parents, STL/Midwest PANDAS Support. Permission was requested
but not granted from the Facebook group PARENTS OF CHILDREN WITH
PANDAS/PANS/LYME/TICK-BORNE DISEASES. The administrators responded
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without permission stating that because this study is only examining PANDAS and not
PANS, they did not think it would appeal to their group members. Permission was also
requested and received from the Aspire administrator. Aspire PANS/PANDAS is a
national outreach partnership program through the National Institute of Mental Health.
Aspire sends a monthly electronic newsletter to subscribers who have input their
information on their website in order to receive the monthly newsletter. This information
is not visible to the public.
PANDAS Facebook support groups serve as a social media resource for
caregivers of children with PANDAS. These networks collaborate with experts, build
public awareness, and serve as a resource and support to those providing care to
PANDAS patients. The Aspire network states that the goal of the newsletter is to keep the
community up to date with PANS/PANDAS news and information.
Inclusion criteria of participants included an official PANDAS diagnosis from a
medical doctor, English as primary language, and being the legal parent of a child with
PANDAS. Cresswell and Poth (2018) note that phenomenological study sample sizes can
range from 1 to 325. This study was a multi-series case study with an aim to understand
similarities and differences of factors in remission from PANDAS parent perspectives. A
sample size of a minimum of 50 respondents of the questions allowed for logical
generalizations and themes to emerge from the closed-ended data, and this seemed a
logical sample size due to prior studies related to PANDAS outcomes (Brown et al.,
2017; Calaprice et al., 2018; Kovacevic et al., 2015; Latimer et al., 2015; Leon et al.,
2018;).
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Study Procedures
The 16-question survey in this study is original and specifically designed for this
study. Since no previous studies involving parental perceptions of PANDAS remission
could be located, it was necessary to create an original survey for this study. Digital
platforms for symptom tracking in PANS/PANDAS are being studied (Harris et al.,
2021). These platforms are new and require further research. The information obtained
from these platforms will be a helpful tool if released for data extrapolation in future
studies.
Upon IRB approval, the Facebook group and Aspire program administrators were
sent messages requesting the survey invitation be posted to the Facebook group and
monthly electronic Aspire newsletter (See Appendix C). Upon receiving permission, the
survey invitation to participate was posted on the Facebook group pages and included in
the Aspire email newsletter. The survey invitation included the link to the Qualtrics
survey. Respondents clicking the link on the Facebook page or in the electronic
newsletter directed them to the survey informed consent and introduction, which includes
the process, procedures, inclusion criteria, and informed consent with researcher contact
information (See Appendix D).
Upon consent, participants were directed to the survey page for completion (See
Appendix A). Surveys were completed anonymously, with no identifying information of
participants being collected. Data was stored on a password-protected computer using
multi-factor authentication. Only the researcher has access to the data. Participants could
choose not to participate at any time prior to submitting the survey by closing their
internet browser. The informed consent was the introduction to the survey, and
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participants could choose not to participate by closing their internet browser. Consent to
participate directed participants to begin the survey on the following page. The first three
questions on the survey are the inclusion criteria questions. Answering “no” to any of the
inclusion questions automatically redirected the respondent to the end of the survey using
the Skip-Logic feature in Qualtrics. There is no direct risk or benefit to participants. The
benefit to society will be increased research on PANDAS.
Instrumentation and Measurement
This study used Wolcott’s (1994) approach to validation with the premise that in
this study validity of a survey tool would neither guide nor inform the qualitative
research, as the goal was to gain a better understanding of PANDAS remission
(Cresswell & Poth, 2018, p. 255). At the time of this study, no valid instrument exists for
the measurement of PANDAS remission, nor has the definition of remission in PANDAS
been clearly defined. Wolcott (1994) states that understanding is better than validity, and
the goal of this study was to gain better understanding of PANDAS remission (Cresswell
& Poth, 2018, p. 255). The sampling process and emergence of patterns in data analysis
allow generalizations of information that can be used as building blocks in future
research. The 16-question survey in this study was original and specifically designed for
this study. Since no previous studies involving parental perceptions of PANDAS
remission could be located, it was necessary to create an original survey for this study.
Other studies of remission in other diseases have used the DAS28 to measure remission;
however, these studies state that further defining of remission using this tool is needed
(Felson, 2011; Gul et al., 2021; Wilhelm et al., 2016).

75
Understanding the thoughts, feelings, and experience of the participants is the
goal of the study; however, the questions allow for certain research questions to be
answered. Survey responses were anonymous, and no identifying information was
requested from survey participants. The informed consent was the introduction to the
survey, and participants could choose not to participate or consent by closing their
internet browser. Consent to participate directed participants to begin the survey on the
following page. The first three questions on the survey were the inclusion criteria
questions. Answering “no” to any of the inclusion questions automatically redirected the
respondent to the end of the survey using the Skip-Logic feature in Qualtrics. Records are
kept under the login of only the author of this study on the Qualtrics platform and will be
retained for a minimum of three years per IRB regulations. Clicking the survey link on
the Facebook group post or newsletter invitation directed participants to a consent form
that details the purpose and procedures of the study as well as researcher contact
information and informed consent before the decision to participate (See Appendix D).
Data Analysis
The data gathered from the survey were analyzed and checked for emerging
patterns using IBM SPSS Statistics 28. Cresswell and Poth (2018) recommend
conducting cross-case theme analysis in order to examine if patterns or themes emerge.
The survey responses were analyzed using Pearson and Point Biserial correlations and
frequency distributions to analyze generalizable patterns using SPSS software.
Using the bivariate analysis feature in SPSS, variables of the survey related to
remission were entered and compared using IBM SPSS Statistics 28 software. Bivariate
correlations are generally used to describe two or more phenomena happening together,
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which can lead to future cause-and-effect studies to see if the phenomena occurring
together provides evidence of causation. A bivariate point biserial correlation was
conducted on age at onset and presence of remission, symptom severity and presence of
remission, length of illness and presence of remission, and gender and presence of
remission.
Using the frequency distribution feature in IBM SPSS Statistics 28, frequency
distributions were used to determine frequencies of males and females diagnosed with
PANDAS, frequency of severity of disorder, frequency of what parents consider most
effective treatments for reaching remission, frequency of what parents consider most
effective treatments for remission maintenance, frequency of symptoms of PANDAS
after puberty, and the frequency of symptom flares in remission.
Delimitations, Assumptions, and Limitations
Limitations of this study are the parents’ perceptions, whether it is mother or
father completing the survey, as mothers and fathers could have different perceptions of
the PANDAS experience. Another limitation could be recall bias, as parents may not
clearly remember lengths of time or symptom severity. Additional limitations include
conservatism, regressive bias, or consistency bias, as parents may not remember exactly
how much a treatment helped or may not remember how bad or good symptoms or
treatment effects were at a particular time.
A delimitation of this study is that it will not address specific brands, doses, or
length of time various treatments were used, as many PANDAS patients use more than
one treatment. Another delimitation of this study is lack of clinical confirmation of
diagnosis. Another delimitation of this study is the use of an original survey rather than
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an instrument that has been sufficiently tested for reliability and validity. PANDAS
remission literature is scarce, therefore there is not enough published research to employ
quantitative experimental studies to determine true clinical remission factors at this time.
Therefore, results of this study are limited by parental perceptions, but will serve as a
basis for future research using quantitative techniques.
An assumption of this study is the understanding of the concept of remission. This
word could have different meaning to different audiences related to chronic conditions. In
other studies, related to remission in lupus and rheumatoid arthritis, differences in the
definition of remission include remission being defined as no clinical signs of disease
activity or disease activity at a low enough level that the symptoms are no longer
troublesome to the patient (Wilhelm et al., 2016). Remission in PANDAS will need to be
defined to address disease activity levels and if remission includes maintenance
treatment. The assumption of the researcher is that remission is defined as no longer
experiencing PANDAS symptoms, and does not specify remission as remission without
treatment or remission while on treatment. Wilhelm et al. (2016) states that the
respondents of a study created variance in the time it takes to reach remission because of
the participant’s definition of remission. Therefore, having a clear definition of PANDAS
remission in the future will be important in future studies.
Summary
The purpose of this qualitative phenomenological case study was to explore
parents’ perceptions of factors contributing to the remission of PANDAS and examine if
age, symptom severity, and length of illness are related to remission. Future research
should be aimed at creating practitioner awareness to lead to more timely and appropriate
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treatment of patients, and exploring which treatment methods are most effective in
reaching remission of PANDAS. Future studies related to remission should include a
clear definition of remission in PANDAS, and an instrument that can be used to measure
the presence of remission in PANDAS patients.
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CHAPTER 4: RESULTS
Overview
The purpose of this qualitative phenomenological case study was to explore
parents’ perceptions of factors related to PANDAS remission. Parents of children
diagnosed with PANDAS were recruited through Facebook PANDAS support groups and
the National Institute of Mental Health Outreach Partnership Program Aspire
PANS/PANDAS newsletter and followed a link to a Qualtrics survey containing 16
questions related to their perception of remission. Inclusion criteria included an official
diagnosis of PANDAS from a medical doctor, being the legal parent or guardian of the
PANDAS patient, with English as the primary language. This study sets a foundation for
future studies to explore why and how various treatments are more or less effective, will
serve as a starting point for future experimental studies on treatment methods, and can
serve as a roadmap for families with a recent PANDAS diagnosis.
Descriptive Results
This study used critical case sampling, which allows for logical generalizations of
remission experiences and provides maximum application of information to other cases
of PANDAS families that have not yet reached remission (Cresswell & Poth, 2018, p.
159). This study took a direct interpretation approach, which allowed the researcher to
look at the instance of remission in PANDAS and extrapolate the data in more
meaningful ways (Cresswell & Poth, 2018, p. 206). This study used Wolcott’s (1994)
approach to validation with the premise that in this study validity of a survey tool would
neither guide nor inform the qualitative research, as the goal was to gain a better
understanding of PANDAS remission (Cresswell & Poth, 2018, p. 255). Wolcott (1994)
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states that understanding is better than validity, and the goal of this study was to gain
better understanding of PANDAS remission (Cresswell & Poth, 2018, p. 255).
The sampling process and emergence of patterns in data analysis allows
generalizations of information that can be used as building blocks in future research.
This study included 16 survey questions on Qualtrics to be answered by parents of
children diagnosed with PANDAS.
The data gathered from the survey was analyzed and checked for emerging
patterns using IBM SPSS Statistics 28. Cresswell and Poth (2018) recommend
conducting cross-case theme analysis in order to examine if patterns or themes emerge.
The survey responses were analyzed using Pearson and Point Biserial correlations and
frequency distributions to analyze generalizable patterns using SPSS software. Pearson’s
r is a correlation used when both variables are scale, and point biserial correlations are
used when one variable is scale and one is nominal and dichotomous. This study used a
.05 level of significance for two-tailed tests, with a critical value of the Pearson r of
.2050.
Using the bivariate analysis feature in SPSS, variables of the survey related to the
presence of remission were entered and compared using IBM SPSS Statistics 28
software. Bivariate correlations are generally used to describe two or more phenomena
happening together. A bivariate point biserial correlation was conducted on age at onset
and presence of remission, symptom severity and presence of remission, length of illness
before diagnosis and presence of remission, and gender and presence of remission.
Using the frequency distribution feature in IBM SPSS Statistics 28, frequency
distributions were used to determine frequencies of males and females diagnosed with
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PANDAS, frequency of severity of disease, frequency of what parents consider most
effective treatments for reaching remission, frequency of what parents consider most
effective treatments for remission maintenance, frequency of symptoms of PANDAS
after puberty, frequency of symptom flares in remission, and frequency of how long
reaching remission takes.
Participants
A total of 87 parents participated in the study. Participants were parents of
children diagnosed with PANDAS. The parents answered questions about their children.
The mean age of PANDAS onset was 7.1 years (range 1-18, SD=3.56) and current mean
age is 13.4 years (range 4-30). Participants were 67.8% male and 32.2% female (n=87,
59 male, 28 female). Mean age at beginning of PANDAS treatment is 9.0 years (range 428, SD=4.18). Mean age at PANDAS onset for males is 6.5 years (n=59) and mean age at
PANDAS onset for females is 8.3 years (n=28). Mean age at PANDAS diagnosis and
treatment for males is 8.41 years (n=59, SD=3.67). Mean age at PANDAS diagnosis and
treatment for females is 10.32 (n=28, SD=4.93). The mean length of time between
symptom onset and receiving PANDAS diagnosis to begin PANDAS treatment is 23.75
months (n=87, range 0-180).
Evidence of Quality
Mack et al., (2005) describes qualitative research as seeking to explore
phenomena using more flexible instruments in order to describe and explain
relationships. Evidence of quality can be viewed through a sampling of survey responses
(See Appendix E). This study used an original survey to explore parents’ perceptions of
factors of remission in PANDAS. The survey was approved by the Institutional Review
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Board of Liberty University and permissions from group administrators for advertisement
of the study were granted (See Appendix B). For assurance of research quality and
timeliness, 80% of sources cited in this study were current within the last five years.
Rallis and Rossman (2012, p. 18) state that the goal of qualitative research is learning by
transforming data into information that can be used. Phenomenology creates a description
of what the participants in the study experienced and how the experience happened, and it
aims to capture the essence of the phenomenon (Creswell & Poth, 2018, p. 201). The
researcher transformed the data from the study into information that can guide areas for
future PANDAS research. Qualitative data generally uses codes as a method of
organizing data. Codes for this study are explained in notation format below the
respective tables.
Study Findings
The purpose of this qualitative phenomenological case study was to explore
parents’ perceptions of factors related to PANDAS remission. Parents of children
diagnosed with PANDAS were recruited through Facebook PANDAS support groups and
followed a link to a Qualtrics survey containing 16 questions related to their perception of
remission. Inclusion criteria included an official diagnosis of PANDAS from a medical
doctor, being the legal parent or guardian of the PANDAS patient, with English as the
primary language.
The goal of this study was to better understand the factors involved in remission
for PANDAS patients according to parents’ perceptions. Therefore, this research was best
suited for a qualitative study to allow for the understanding of the lived experience of
PANDAS families remission experiences rather than testing cause and effect
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relationships. According to Creswell and Poth (2018, p. 8), qualitative research begins
with an assumption and uses interpretive and theoretical frameworks to inform the study
to address research problems by addressing a group with a human problem, in this case,
PANDAS remission.
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RQ1: According to parents’ perceptions, which treatment is most effective in achieving
remission?
Using the frequency distribution feature in SPSS, a frequency distribution was
used to examine frequency of parent-reported effective treatments for achieving
remission. According to parents (n=87), antibiotics had the single greatest healing effect
(n=34, 39.1%). Followed by IVIG/Therapeutic Plasma Exchange (n=16, 18.4%), then
undescribed “other” (n=13, 14.9%), then anti-inflammatory over-the-counter drugs (n=7,
8.0%), tonsillectomy and prescription steroid ranked equally, (tonsillectomy, n=5, 5.7%,
prescription steroid, n=5, 5.7%), followed by non-prescription supplements (n=4, 4.6%),
Q6 Which treatment had the greatest healing effect, and last dietary changes (n=3, 3.4%).
See Figure 1.
Figure 1
Treatment with Greatest Healing Effect
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RQ2: According to parents’ perceptions, how long does achieving remission take?
Using the frequency distribution feature in SPSS, a frequency distribution was
used to examine frequency of parent-reported length of time (in months) for remission to
be reached. This study revealed that, according to parents’ perceptions, the mean months
to remission was 18.64 (n=84). See Figure 2. Of the 87 survey participants, 3 had missing
data, 54 stated they had achieved remission and 30 stated they had not reached remission.
Figure 2
Length of Time to Reach Remission

86
RQ3: According to parents’ perceptions, is length of PANDAS illness prior to receiving
diagnosis and treatment related to presence of remission?
Using the bivariate correlation feature in SPSS, a Point Biserial correlation was
used to examine the parent-reported length of time (in months) that children were
undiagnosed/untreated compared to presence of remission. The findings of this study
indicate that the length of PANDAS illness prior to receiving diagnosis and treatment is
not related to achieving remission. See Figure 3. A Point Biserial Correlation revealed
there is not a statistically significant relationship between the length of time of illness
before diagnosis and treatment and presence of remission, r (85) = 0.03, p > .05 (twotailed). Using the bivariate correlation feature in SPSS, a Pearson’s r correlation was used
to examine the parent-reported length of time (in months) before receiving
treatment/diagnosis and the length of time (in months) to reach remission. A Pearson’s r
Correlation revealed there is not a statistically significant relationship between the length
of time before receiving diagnosis and treatment and the length of time to reach
remission, r (87) = .11, p>.05 (two-tailed). See Figure 4.
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Figure 3
Length of Time to Receive Diagnosis and Presence of Remission

Figure 4
Months to Receive Diagnosis and Treatment and Months to Remission
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RQ4: According to parents’ perceptions, is severity of PANDAS symptoms related to
achieving remission?
Using the frequency distribution feature in SPSS, a frequency distribution was
used to examine parent-reported symptom severity. According to parents’ perceptions,
52.9% of cases are severe (n=46), 40.2% of cases are reported as moderate (n=35), and
6.9% are reported as mild (n=6). See Figure 5. Using the bivariate correlation feature in
SPSS, a Point Biserial correlation was used to examine the parent-reported PANDAS
symptom severity and presence of remission. The results of this study indicate the
severity of PANDAS symptoms are not related to presence of remission. See Figure 6. A
Point Biserial correlation revealed there is not a statistically significant relationship
between symptom severity and length of time to reach remission, r (85) = .02, p > .05
(two-tailed).
Figure 5
Parents’ Perception of PANDAS Symptom Severity
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Figure 6
Symptom Severity and Presence of Remission

Note. Remission reached coded 1 (yes) and 2 (no).
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RQ5: According to parents’ perceptions, is age of PANDAS patient at symptom onset
related to achieving remission?
Using the bivariate correlation feature in SPSS, parent-reported age of PANDAS
patient (in years) at PANDAS symptom onset and presence of remission was examined.
A Point Biserial correlation revealed there is not a statistically significant relationship
between age at onset and presence of remission, r (85) = 0.04, p> .05 (two-tailed). See
Figure 7.
Figure 7
PANDAS Onset Age and Presence of Remission

Note. Remission reached is coded 1 (yes) and 2 (no).
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RQ6: According to parents’ perceptions, is presence of puberty related to PANDAS
symptoms?
Using the frequency distribution feature in SPSS, parent-reported presence of
puberty’s effect on PANDAS symptoms was examined. According to parents (n=86), 37
of the children have not yet experienced puberty. Of the remaining, (n=49), 8 indicated
less PANDAS symptoms after puberty, 11 indicated more PANDAS symptoms after
puberty, and 30 indicated puberty did not have an effect on PANDAS symptoms. See
Figure 8.
Figure 8
Puberty and Effect on PANDAS Symptoms
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RQ7: According to parents’ perceptions, are symptom flares experienced after achieving
remission?
Using the frequency distribution feature of SPSS, a frequency distribution was
used to examine parent-reported PANDAS symptom flares experienced after remission
had been achieved. According to parents’ perceptions (n=84), 32 stated there are still
symptom flares in remission, 9 indicated all symptoms had resolved, 18 said they have
symptoms that have never resolved while in remission, and 25 parents indicated they
have not yet reached remission. See Figure 9.
Figure 9
Symptom Flares Experienced in Remission
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RQ8: According to parents’ perceptions, is gender related to presence of remission?
Participants were 67.8% male and 32.2% female (n=87, 59 male, 28 female).
Mean age at beginning of PANDAS treatment is 9.0 years (range 4-28, SD=4.18). Mean
age at PANDAS onset for males is 6.5 years (n=59) and mean age at PANDAS onset for
females is 8.3 years (n=28). Mean age at PANDAS diagnosis and treatment for males is
8.41 years (n=59, SD=3.67). Mean age at PANDAS diagnosis and treatment for females
is 10.32 (n=28, SD=4.93). Using the bivariate correlation feature in SPSS, gender was
compared to presence of remission. This study did not reveal a statistically significant
relationship between gender and presence of remission, r (85) = .07, p > .05 (two-tailed).
See Figure 10.

Figure 10
Presence of Remission and Gender
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RQ9: According to parents’ perceptions, what is the most effective treatment for
remission maintenance?
Using the frequency distribution feature in SPSS, parent-reported most effective
treatments for remission maintenance were compared. This study revealed that parents
(n=87) consider prescription drugs most effective for remission maintenance, (n=34),
followed by over-the-counter supplements or lifestyle changes to maintain remission
(n=20), followed by no maintenance drugs of any kind required (n=8). Of the 87 parents
surveyed, 25 indicated they had not yet reached remission. See Table 2.
Table 2
Parents’ Perception of Most Effective Treatment for Remission Maintenance
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Summary
The purpose of this study was to explore parents’ perceptions related to factors of
remission in PANDAS. Findings from this study are supportive of a previous study by
Latimer et al. (2015) that length of illness is not related to presence of remission. This
study is also supportive of prior research that PANDAS occurs more in males than
females, generally with onset at age 6-8 years (Kovacevic et al., 2015; Swedo et al.,
2015). This study also found that the mean length of time children were misdiagnosed or
undiagnosed from symptom onset to beginning PANDAS treatment was 23.75 months
(n=87). This study did not find statistically significant correlations between PANDAS
symptoms, age, and severity related to remission. This study found that while in
remission (n=59), the majority of children, 85%, still have PANDAS symptoms (n=50).
This study found that parents attribute antibiotics to the greatest PANDAS healing
treatment effect (n=34) and IVIG as the second most important healing treatment (n=16).
The findings of this study highlight the need for increased practitioner and community
awareness of PANDAS diagnosis and treatment methods as well as future research
needed to better understand PANDAS remission and treatments that could lead to lasting
remission.
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CHAPTER 5: DISCUSSION
Overview
The purpose of this qualitative phenomenological case study was to explore
parents’ perceptions of factors contributing to the remission of PANDAS. This study
aimed to discover patterns in reaching PANDAS remission related to age, severity of
illness, treatment methods, and symptom exacerbations. The study used a 16-question
original survey on Qualtrics related to parents’ perceptions of factors of remission in
PANDAS. Findings from this study can be used in future research to discover cause and
effect relationships between treatment methods, age, and symptom severity to better
guide treatment protocols in the future.
Summary of Findings
The purpose of this study was to explore parents’ perceptions related to factors of
remission in PANDAS. Findings from this study are supportive of a previous study by
Latimer et al. (2015) that length of illness is not related to presence of remission. This
study is also supportive of prior research that PANDAS occurs more in males than
females, generally with onset at age 6-8 years (Kovacevic et al., 2015; Swedo et al.,
2015). This study also found that the mean length of time children were misdiagnosed or
undiagnosed from symptom onset to beginning PANDAS treatment was 23.75 months
(n=87). This study did not find statistically significant correlations between PANDAS
symptoms, age, and severity related to remission. This study found that while in
remission (n=59), the majority of children, 85%, still have PANDAS symptoms (n=50).
This study found that parents attribute antibiotics to the greatest PANDAS healing
treatment effect (n=34) and IVIG as the second most important healing treatment (n=16).
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The findings of this study highlight the need for increased practitioner and community
awareness of PANDAS diagnosis and treatment methods as well as future research
needed to better understand PANDAS remission and treatments that could lead to lasting
remission.
Discussion of Findings
The findings of this study are supportive of prior research indicating that length of
illness does not appear to be related to remission (Latimer, 2015). The mean length of
time children were ill with PANDAS symptoms before receiving diagnosis and treatment
in this study was 23.75 months (n=87). LaRusso et al. (2022) discusses gaps in diagnosis
and care due to logistics of medical coverage thus compromising children’s health and
development. LaRusso et al. (2022) states that patients with PANS/PANDAS often
receive untimely care. Rea et al. (2021) noted that worsening school performance,
increased anxiety, irritability, and aggressivity all increase with symptom exacerbations.
This study is evidence of the need for increasing practitioner and community awareness
for PANDAS for children to receive a timely diagnosis and adequate care to help children
with PANDAS thrive.
There was not a significant relationship between age of PANDAS onset, length of
PANDAS illness without treatment, PANDAS symptom severity, or gender and presence
of remission. The findings of this study are supportive that PANDAS affects more males
than females, and that the typical age of onset is between 6-8 years (Harris et al., 2021;
Kovacevic et al., 2015; Swedo et al., 2015). This study did not find a significant
relationship between presence of puberty and presence of remission. In a study by
Gruijter et al. (2021) a bidirectional relationship between puberty and autoimmune
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rheumatic disease was found. Further research can be conducted related to long-term
outcomes after the presence of puberty and remission to see if any relationship exists
between age, puberty, and PANDAS remission.
Another important element of this study is the parent-reported effective treatment
methods, with antibiotics and IVIG/TPE being the highest ranked effective treatment
methods by parents. These findings suggest the importance of increasing practitioner
awareness and training to provide proper care to PANDAS children. Pandas Physicians
Network currently gives recommendations on which antibiotics seem to be most helpful
in treating PANDAS symptoms, but more research is needed to determine what dosing
and length of treatment is needed to reach and maintain remission. In a study by Leon et
al. (2018), 72% (n=33) of participants experienced at least one PANDAS symptom
exacerbation within the 6-57 month period following IVIG. Additional research related to
IVIG dosing and frequency is needed to determine prescription parameters that help to
not only quickly reach but also maintain remission. A study by Cross et al. (2021)
concluded in a case study that with treatment over 31 consecutive months using various
antimicrobials and three courses of IVIG, the child reached complete remission. In a
study by Gromark et al. (2021) there was not a distinction made between
PANS/PANDAS, however, the conclusions state that although full remission was rare,
the majority of children with PANS significantly improved over a 3-year period post
treatment.
This study also sheds light on the need for continued research related to
PANDAS, such as clear definition of PANDAS remission and further research to create
remission maintenance protocols. The study by Wilhelm et al. (2021) found that
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achieving remission was frequent, but durable remission was rare. Regarding symptoms
in remission, this study concludes of the participants, (n=84), 32 stated there are still
symptom flares in remission, 9 indicated all symptoms had resolved, 18 said they have
symptoms that have never resolved while in remission, and 25 parents indicated they
have not yet reached remission. In a study by Leon et al. (2018), at follow-up, 29 of the
33 participants were experiencing no or only subclinical OCD symptoms. Of the
remaining 4 with clinically significant OCD symptoms, one child was currently
experiencing a symptom exacerbation at the time of follow-up, one child had
discontinued all treatments before all symptoms had resolved, and two children had
persistent OCD and remained in treatment (Leon et al., 2018). In a study by Colvin et al.
(2021), the cognitive, graphomotor, and psychosocial challenges PANDAS patients face
were ongoing and significant academic difficulty and emotional, behavioral, and social
concerns remained after symptom resolution. This study provides a foundation for future
studies to explore in more detail the concept of remission in PANDAS.
In a retrospective study of 40 patients, a study by Latimer et al. (2015) concluded
that improvement with therapeutic plasma exchange was not associated with the duration
of illness. In a case study by Cross et al. (2021), the researchers conclude that after a span
of 31 months of illness and treatment with antimicrobials and IVIG, the patient reached
complete remission. Mohammad and Dale (2018) find in PANS/PANDAS patients, there
is a risk of relapse in the majority of patients. Gromark et al. (2021) concluded in PANS
patients that had both chronic and non-chronic symptoms, the two groups had similar
symptom severity at baseline, but the chronic course group had more impairment, which
could suggest that both early onset and degree of impaired function could be useful
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predictors of prognosis. Gromark et al., (2021) states that, due to their small sample size,
they are not able to predict prognostic factors, but future research with larger samples
should make this a priority. It is not clear if symptom flare management is life-long or if
remission includes complete symptom recovery with no further exacerbations.
Implications
PANDAS Network estimates approximately 1 in 200 children suffer from
PANDAS (Leonard & Swedo, 2001). This number is hard to estimate because it is
believed so many children go misdiagnosed due to lack of practitioner knowledge on
PANDAS. The findings of this study highlight the need for increased practitioner and
community awareness of PANDAS diagnosis and treatment methods as well as future
research needed to better understand PANDAS remission and treatments that could lead
to lasting remission. Increasing awareness and understanding of PANDAS will lead to
more children receiving timely diagnosis. Although length of illness was not found to be
related to presence of remission, it is important to ensure children receive timely care in
order to prevent undue lasting symptoms and family turmoil due to PANDAS. Cross et
al. (2021) conducted a case study that described PANDAS symptom exacerbations as
incapacitating stating that the symptoms impact the child’s personal, family, social, and
academic domains. Rea et al. (2021) noted that worsening school performance, increased
anxiety, irritability, and aggressivity all increase with symptom exacerbations. In a study
by Vlist et al. (2019) researchers sought to understand participation in childhood in those
with chronic disease. Vlist et al. (2019) found that children with chronic disease learn to
carefully weigh participation against their current and/or future needs and assess the risk
versus benefit of their choices and chronic condition needs. Additional research for
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management of the disease and potential accommodations required during PANDAS
symptom exacerbations is also needed in order to help children with PANDAS thrive.
PANDAS affects the entire family, as Ringer and Roll-Pettersson (2022) discuss
the negative effects PANS/PANDAS can have on parents, including the chronicity of the
condition, appraisals of feeling helpless, and difficulty receiving treatment, suggests that
parents of PANS/PANDAS are particularly at risk to experience high levels of
psychological stress. Increasing awareness and proper diagnosis and treatment of
PANDAS could lead to better mental health outcomes of the families involved, and in
turn the general public.
Limitations
Limitations of this study are the parents’ perceptions, whether it is mother or
father completing the survey, as mothers and fathers could have different perceptions of
the PANDAS experience. Another limitation could be recall bias, as parents may not
clearly remember lengths of time or symptom severity. Additional limitations include
conservatism, regressive bias, or consistency bias, as parents may not remember exactly
how much a treatment helped or may not remember how bad or good symptoms or
treatment effects were at a particular time.
A delimitation of this study is that it did not address specific brands, doses, or
length of time various treatments were used, as many PANDAS patients use more than
one treatment. This study found that antibiotics had the greatest healing treatment effect
(n=34), but the type or dosage of antibiotic is unknown. The treatment with the next
greatest healing effect was reported to be IVIG/TPE (N=16), but the type or dosage is
unknown.
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Another delimitation of this study is lack of clinical confirmation of diagnosis.
This study did not receive medical records of participants to confirm PANDAS diagnosis
from a medical professional.
Another delimitation of this study is the use of an original survey rather than an
instrument that has been sufficiently tested for reliability and validity. This study used a
16-question survey on Qualtrics answered by parents of children diagnosed with
PANDAS. Digital platforms for symptom tracking in PANS/PANDAS are being studied,
which could lead to helpful data in understanding the relapsing/remitting course of
PANDAS (Harris et al., 2021).
PANDAS remission literature is scarce, therefore there is not enough published
research to employ quantitative experimental studies to determine true clinical remission
factors at this time. Therefore, results of this study are limited by parental perceptions,
but will serve as a basis for future research using quantitative techniques.
An assumption of this study is the understanding of the concept of remission. This word
could have different meaning to different audiences related to chronic conditions. In other
studies, related to remission in lupus and rheumatoid arthritis, differences in the
definition of remission include remission being defined as no clinical signs of disease
activity or disease activity at a low enough level that the symptoms are no longer
troublesome to the patient (Wilhelm et al., 2016). Remission in PANDAS will need to be
defined to address disease activity levels and if remission includes maintenance
treatment. The assumption of the researcher is that remission is defined as no longer
experiencing PANDAS symptoms, and does not specify remission as remission without
treatment or remission while on treatment. Wilhelm et al. (2016) states that the
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respondents of a study created variance in the time it takes to reach remission because of
the participant’s definition of remission. Therefore, having a clear definition of PANDAS
remission in the future will be important in future studies.
Recommendations for Future Research
Future studies on PANDAS should be aimed at creating awareness for timely
diagnosis and treatment. This study found that children were misdiagnosed or
undiagnosed with PANDAS for an average length of time of 23.75 months. Although
another finding of this study is that length of illness prior to receiving treatment was not
found to be statistically significant in correlation to presence of remission, lack of proper
diagnosis leads to unnecessary trauma and symptoms for both child and family. Rea et al.
(2021) noted that worsening school performance, increased anxiety, irritability, and
aggressivity all increase with symptom exacerbations. In a study by Vlist et al. (2019)
researchers sought to understand participation in childhood in those with chronic disease.
Vlist et al. (2019) found that children with chronic disease learn to carefully weigh
participation against their current and/or future needs and assess the risk versus benefit of
their choices and chronic condition needs. Future studies can be aimed at creating
awareness for timely diagnosis and treatment along with investigative research to
determine more specific factors in remission, such as what causes lasting symptoms or
relapse and what can be done to manage and/or treat these symptoms.
Additional research needed for PANDAS should include investigative research to
determine more specific factors in remission. This will include specifying PANDAS
remission definitions, what causes lasting symptoms or relapse, and what can be done to
manage and/or treat these symptoms. Future studies on treatments, such as how to reach
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remission quickly and maintain it, are also needed, as 85% of participants in remission
state they still experience PANDAS symptoms while in remission.
This study will allow for future research that can describe evidence of causation
for treatment methods and factors of remission in PANDAS. This study provides several
pathways for future research to continue on PANDAS treatment methods. By
investigating the treatments parents reported to be most effective in remission, future
studies can delve further into each area which can lead to future cause-and-effect studies
to see if the phenomena occurring together provides evidence of causation. Future studies
could explore which types of treatments, such as brands and dosing, have the best results
for lasting remission.
Summary
The purpose of this study was to explore parents’ perceptions of remission in
PANDAS. Previous research could not be located that had explored factors of remission
in PANDAS. This study aimed to bring hope to families suffering with PANDAS and
both highlight areas needed for future research and to lead to movements to increase
practitioner and community awareness of PANDAS to help more children and families
reach proper diagnosis and treatment sooner without having so much time suffering.
Cross et al. (2021) described PANDAS symptom exacerbations as incapacitating and
affecting the child’s personal, family, social, and academic domains. The aim of this
study, to provide hope to families and areas for future research, has been highlighted.
Jeremiah 1:5 can serve as a message for children with PANDAS, “Before I formed you in
the womb I knew you, before you were born I set you apart; I appointed you as a prophet
to the nations.” Although the concept of remission in PANDAS requires much more
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scientific research, faith remains of high importance. As the findings of this study
indicate, there is hope in healing for those suffering with PANDAS, and many paths to
future research that will change lives of children diagnosed with this disorder.
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APPENDIX A: SURVEY QUESTIONS
Yes/No Screening Questions:
Has your child been diagnosed with PANDAS from a medical doctor?
Are you at least 18 years of age or older?
Are you the parent of a child diagnosed with PANDAS?

What is the gender of your child? (Fill in the blank)
How old was your child at symptom onset (in years)? (Fill in the blank)
How old is your child now (in years)? (Fill in the blank)
How old was your child when they started PANDAS treatment (in years)? (Fill in the
blank)
How long was the time between symptom onset and receiving official PANDAS
diagnosis (in months)? (Fill in the blank)
In your opinion, which single treatment had the greatest healing effect? (Choose
One: Antibiotics, Intravenous Immunoglobulin (IVIG) or Therapeutic Plasma Exchange
(TPE), Tonsillectomy, Non-Prescription Supplements such as vitamins, Dietary Changes,
Anti-Inflammatory Over-the-Counter drugs such as ibuprofen, prescription steroid, Other
At the height of your child’s symptoms, would you classify them with mild,
moderate, or severe PANDAS? Choose one: mild, moderate, severe
How long does/did a typical PANDAS flare last (in weeks)? Fill in the blank)
Has your child reached complete remission? (yes/no)
If your child has reached remission, how long did reaching remission take (in
months)? Fill in the blank, N/A remission not reached
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If your child has reached remission, does your child still experience symptom flares
or lasting symptoms? Choose one: Yes, still has PANDAS symptoms that have never
resolved, No, all PANDAS symptoms resolved, sometimes still has flares, not applicableremission not reached
Does your child take any medications or supplements to maintain remission? Choose
One: Yes, prescription medications are used to maintain remission, yes, over the counter
supplements and/or lifestyle changes are used to maintain remission, no, prescription
medications or supplements are not used to maintain remission, not applicable remission
not reached
If your child has went through puberty, did puberty have any effect on PANDAS
symptoms or remission?
Choose One: Yes puberty had an effect, less PANDAS symptoms after puberty, yes
puberty had an effect, more PANDAS symptoms after puberty, puberty did not have an
effect on PANDAS symptoms, not applicable- my child has not experienced puberty
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APPENDIX B: SURVEY RECRUITMENT
Survey invitation to be posted on social media group pages and Aspire Newsletter,
written by Janice Weddle and given to Facebook group administrators of the following
pages and director of the Aspire outreach program:

Permission granted:
Facebook: PANDAS- Pediatric Autoimmune Neuropsychiatric Disorder Associated
w/Strep
Administrators: Kristy Streb, Patricia Mom, Michelle Barton, Kelly Parks

ASPIRE PANS PANDAS Newsletter
Administrator: Gabriella True

Facebook: PANDAS PARENTS
Administrator: Daren Walsh

Facebook: STL/Midwest PANDAS Support
Administrator: Kelly Wooldridge

Permission Not Granted:
Facebook: PANDAS Resource Network
Administrators: Lynn Johnson, Suzanne Butler Li
No response received
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Facebook: PARENTS OF CHILDREN with PANDAS/PANS/LYME/TICKBORNE
DISESASES
Administators: Julie Searcy Anderson, Deborah Washburn, Melissa Ferwardabell

Permission not granted due to study not investigating PANS

Message:
ATTENTION PANDAS PARENTS: I am conducting research as part of the
requirements for a Doctor of Philosophy degree at Liberty University. The purpose of my
research is to discover parents’ perceptions of remission in PANDAS. To participate,
you must be at least 18 years of age and the parent of a child diagnosed with PANDAS
by a medical doctor, and English must be your primary language. Participants will be
asked to complete a short, anonymous, online survey regarding their experience with
PANDAS remission, which should take about five minutes. If you would like to
participate and meet the study criteria, please follow the link below. A consent document
is provided as the first page of the survey. If you agree to participate in this study, click
the “proceed to survey” button at the bottom of the consent page. Thank you!

To take the survey, click here: {LINK]
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APPENDIX C: ADMINISTRATOR SURVEY PERMISSION

Dear Facebook Group/Newsletter Administrator,

I am a psychology doctoral student at Liberty University, and the mom of an eleven year-old boy diagnosed with PANDAS, located in Southern Missouri. I am requesting
that you would be willing to share a survey in the [(Name of Facebook Group) Facebook
Group page that you are listed as administrator on/in the ASPIRE monthly newsletter],
asking for participation in my study. If you are willing to share the information, I will
send information that you can simply copy and paste to potential participants that has a
description of the study and link to the survey.

As part of my dissertation, I will be conducting a research project on PANDAS. The
purpose of this study is to shed light on PANDAS remission experiences. As a PANDAS
parent myself I understand how incredibly painstaking it is to not have answers on if or
when our children will get better. I am looking for participants, parents of PANDAS
diagnosed children, to complete a survey related to their experiences with remission of
PANDAS. Participants who are a PANDAS parent, received PANDAS diagnosis from a
medical doctor, and whose primary language is English are requested to participate.

The survey is 16 questions. The survey is not expected to take more than 5 minutes. No
identifying information will be requested on the survey. I am committed to protecting
privacy, and all information obtained will be kept secure with confidentiality prioritized.
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There is no compensation for participating in this study, however, the benefit of being in
this study is answering important questions related to PANDAS experiences that can lead
to future research on effective treatment plans and can serve as a path of hope for
PANDAS families. Participants are free to withdrawal or decline for any reason.
Following the link on the survey that will be posted to the group pages will direct
participants to a page with detailed consent information, contact information for the
researcher, and more information on the purpose and procedures of the study.

Please feel free to contact me with questions or concerns, at 417-259-2291. You are also
free to contact my dissertation chair, Dr. Laura Rolen, at llrolen@liberty.edu

Your assistance is very appreciated!

Please let me know if you are willing to allow this survey to be advertised on your group
page. If so, I will send a follow up message with the survey link and description that can
be copied and pasted onto the group page.

Sincerely,

Janice Weddle, M.Ed.
Ph.D. Candidate, Doctor of Psychology, Liberty University
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APPENDIX D: CONSENT

Title of the Project: Pediatric Autoimmune Neuropsychiatric Disorder Associated with
Streptococcal Infection (PANDAS): A Qualitative Study of Parental Perceptions of
Factors in Remission
Principal Investigator: Janice Weddle, M.Ed., Ph.D. Candidate, Liberty University
Invitation to be Part of a Research Study
You are invited to participate in a research study. To participate, you must be the parent
of a child diagnosed with PANDAS by a medical doctor, with English as your primary
language, and at least 18 years old. Taking part in this research project is voluntary.
Please take time to read this entire form and ask questions before deciding whether to
take part in this research.
What is the study about and why is it being done?
The purpose of this study is to explore parents’ perceptions of factors contributing to the
remission of PANDAS. Research studies related to PANDAS remission and long-term
outcomes are scarce and generally inconclusive. This study will look for patterns related
to PANDAS remission experiences that can guide future research.
What will happen if you take part in this study?
If you agree to be in this study, I will ask you to do the following things:
This will be a 16-question online survey using Qualtrics and is only expected to take
approximately five minutes to complete.
How could you or others benefit from this study?
Participants should not expect to receive a direct benefit from taking part in this study.
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Benefits to society include further development on PANDAS research to both guide
future research and assist parents with children with a new PANDAS diagnosis.
What risks might you experience from being in this study?
The risks involved in this study are minimal, which means they are equal to the risks you
would encounter in everyday life.
How will personal information be protected?
The records of this study will be kept private. Research records will be stored securely,
and only the researcher will have access to the records.
Participant responses will be anonymous.
Data will be stored on a password-locked computer with multi-factor authentication.
After three years, all electronic records will be deleted.
Is study participation voluntary?
Participation in this study is voluntary. Your decision whether or not to participate will
not affect your current or future relations with Liberty University. If you decide to
participate, you are free to not answer any question or withdraw at any time prior to
submitting the survey without affecting those relationships.
What should you do if you decide to withdraw from the study?
If you choose to withdraw from the study, please exit the survey and close your internet
browser. Your responses will not be recorded or included in the study.
Whom do you contact if you have questions or concerns about the study?
The researcher conducting this study is Janice Weddle. You may ask any questions you
have now. If you have questions later, you are encouraged to contact her at
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weddlejd@missouri.edu. You may also contact the researcher’s faculty sponsor, Dr.
Laura Rolen, at llrolen@liberty.edu
Whom do you contact if you have questions about your rights as a research
participant?
If you have any questions or concerns regarding this study and would like to talk to
someone other than the researcher, you are encouraged to contact the Institutional
Review Board, 1971 University Blvd., Green Hall Ste. 2845, Lynchburg, VA 24515 or
email at irb@liberty.edu.
Disclaimer: The Institutional Review Board (IRB) is tasked with ensuring that human subjects research
will be conducted in an ethical manner as defined and required by federal regulations. The topics covered
and viewpoints expressed or alluded to by student and faculty researchers are those of the researchers and
do not necessarily reflect the official policies or positions of Liberty University.

Your Consent
[Before agreeing to be part of the research, please be sure that you understand what the
study is about. You can print a copy of the document for your records. If you have any
questions about the study later, you can contact the researcher using the information
provided above.
I have read and understood the above information. I have asked questions and have
received answers. I consent to participate in the study.
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APPENDIX E: EVIDENCE OF QUALITY
Sample Survey Responses

Female 13
weeks No

16

15

36 months

Antibiotics

Not Applicable- Remission not reached

Severe 4
Not applicable-

remission not reached Not applicable- remission not reached

Puberty did

not have an effect on PANDAS symptoms

Female 5

7

5

Drugs (such as ibuprofen)
Sometimes still has flares

0 months

Anti-Inflammatory Over-the-Counter

Severe 16

Yes

Months to Remission: 6

Yes, over-the-counter supplements and/or lifestyle

changes are used to maintain remission

Not applicable- my child has not

experienced puberty

Male 6

13

6

Moderate

12 weeks

one month
Yes

Prescription Steroid

Months to Remission: 1

Sometimes

still has flares Yes, over-the-counter supplements and/or lifestyle changes are used to
maintain remission

Yes puberty had an effect, more PANDAS symptoms after

puberty

Female 9

13

9

Months to Remission: 9

3

Antibiotics

Sometimes still has flares

Mild

4

No

Yes, over-the-counter
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supplements and/or lifestyle changes are used to maintain remission

Not

applicable- my child has not experienced puberty

Female 5

11

5

Months to Remission: 2

1

Antibiotics

Mild

8

Yes

No, all PANDAS symptoms resolved No,

prescription medications or supplements are not used to maintain remission
Puberty did not have an effect on PANDAS symptoms

Female 13

25

20

Months to Remission: 54
resolved

84

None of these Severe 300

Yes

Yes, still has PANDAS symptoms that have never

Yes, prescription medications are used to maintain remission.

Yes

puberty had an effect, more PANDAS symptoms after puberty

Male 4

16

6

Therapeutic Plasma Exchange (TPE)
Months to Remission: 70

12

Intravenous Immunoglobulin (IVIG) or
Moderate

Several at least.

Sometimes still has flares

Yes

Yes, prescription

medications are used to maintain remission. Yes puberty had an effect, less PANDAS
symptoms after puberty

Male 7

10

7

Within a week of onset

Severe 10

Yes

Months to Remission: 2-3

Prescription Steroid
Yes, over-the-counter

supplements and/or lifestyle changes are used to maintain remission
applicable- my child has not experienced puberty

Not

